

**Application
for
United States Letters Patent**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211
2212
2213
2214
2215
2216
2217
2218
2219
2220
2221
2222
2223
2224
2225
2226
2227

CLONING AND USES OF THE GENETIC LOCUS bcl-6

5 The invention disclosed herein was made with Government support under NIH Grant Nos. CA-44029, CA-34775, CA-08748 and CA-37295 from the Department of Health and Human Services. Accordingly, the U.S. Government has certain rights in this invention.

10 This application is a continuation-in-part of United States application Serial No. 08/074,967, filed on June 9, 1993, the contents of which are hereby incorporated by reference.

15 BACKGROUND OF THE INVENTION

Throughout this application various references are referred to within parenthesis. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic citation for these references may be found at the end of each Experimental Detail Section.

25 Non-random chromosomal abnormalities are found in up to 90% of patients with non-Hodgkin's lymphoma (NHL) and have been shown to play an important role in lymphomagenesis by activating proto-oncogenes (1). Some of these translocations, which are associated with specific histologic subsets of NHL, have been characterized at the molecular level. In the t(8;14), t(8;22), and t(2;8) translocations associated with Burkitt Lymphoma, L₃-type acute lymphoblastic leukemia and AIDS-associated non-Hodgkin lymphoma (NHL), a known proto-oncogene, c-myc, was found juxtaposed to the immunoglobulin (Ig) loci (2,3). In the t(14;18) translocation, which is implicated in follicular-type NHL, molecular analysis of the sequences linked to the Ig locus led to the identification of a novel proto-

oncogene, bcl-2 (4-6). The t(11;14)(q13;q32), mainly associated with "mantle zone" lymphoma, appears to involve the juxtaposition of the Ig heavy-chain locus with the bcl-1 locus, the site of the candidate proto-oncogene PRAD-1/cyclin D1 (7,8). These well characterized chromosome translocations are associated, however, with only a fraction of NHL cases, while a number of other recurrent translocations remain to be characterized for their genetic components.

One important example of such cytogenetic abnormalities is represented by various alterations affecting band 3q27. This region is involved in translocations with various chromosomal sites including, but not limited, to those carrying the Ig heavy- (14q32) or light- (2p12, 22q11) chain loci (9,10). Overall, 3q27 breakpoints are detectable in 7-12% of B-cell NHL cases by cytogenetic analysis, with t(3;22)(q27;q11) being the most frequent type detectable in 4-5% of NHL (9). The clinicopathologic relevance of 3q27 breakpoints is underscored by its consistent association with diffuse-type NHL, a frequent and clinical aggressive subtype for which no specific molecular lesion has yet been identified (9).

The recurrence of 3q27 breakpoints in NHL has prompted a search for the corresponding proto-oncogene. This invention discloses the cloning of clustered 3q27 breakpoints from two NHL cases carrying t(3;14)(q27;q32) translocations and the identification of genomic rearrangements within the same breakpoint region in additional NHL cases carrying translocations involving 3q27. Within the same region, a transcriptional unit has been identified, which represents the candidate proto-oncogene (bcl-6) associated with 3q27 translocations in B-NHL.

SUMMARY OF THE INVENTION

This invention provides an isolated vertebrate nucleic acid molecule of bcl-6 locus. This invention provides
5 an isolated vertebrate DNA molecule of bcl-6 locus. This invention provides an isolated vertebrate cDNA molecule of bcl-6. This invention provides an isolated genomic DNA molecule of bcl-6. This invention provides an isolated vertebrate RNA molecule of bcl-6. This
10 invention provides an isolated human nucleic acid molecule of bcl-6 locus.

In addition, this invention provides a nucleic acid molecule comprising a nucleic acid molecule of at least
15 15 nucleotides capable of specifically hybridizing with a sequence included within the sequence of the nucleic acid molecule of bcl-6.

In addition, this invention provides an isolated
20 vertebrate DNA molecule of bcl-6 operatively linked to a promoter of RNA transcription. This invention provides a vector which comprises the isolated vertebrate DNA molecule of bcl-6.

25 In addition, this invention provides the above vector, wherein the isolated nucleic acid molecule is linked to a plasmid.

30 In addition, this invention provides a host vector system for the production of a polypeptide encoded by bcl-6 locus, which comprises the above vector in a suitable host.

35 In addition, this invention provides a method of producing a polypeptide encoded by bcl-6 locus, which comprises growing the above host vector system under suitable conditions permitting production of the

polypeptide and recovering the polypeptide so produced.

5 In addition, this invention provides a polypeptide encoded by the isolated vertebrate nucleic acid molecule of bcl-6 locus. Further, this invention provides an antibody capable of binding to polypeptide encoded by bcl-6 locus.

10 In addition, this invention provides an antagonist capable of blocking the expression of the polypeptide encoded by bcl-6.

15 In addition, this invention provides an antisense molecule capable of hybridizing to the nucleic acid molecule of bcl-6.

20 In addition, this invention provides an assay for non-Hodgkin's lymphoma, a method for screening putative therapeutic agents for treatment of non-Hodgkin's lymphoma and a method for diagnosing B-cell lymphoma.

Finally, this invention provides a method of treating a subject with non-Hodgkin's lymphoma.

BRIEF DESCRIPTION OF THE FIGURES

- Figur 1: Immunoglobulin gene rearrangement analysis of KC1445 and SM1444 DNA. DNA extracted from the cell lines U937 (monocytic leukemia) and SK-N-MC (neuroblastoma) were used as controls for non-rearranged, germ-line Ig genes. In the left panel, the arrow on the left points to the rearranged J_H fragment which does not contain C_μ sequences in KC1445 DNA, while the two arrows on the right point to the two distinct fragments containing J_H or C_μ sequences in SM1444 DNA.
- Figure 2: Molecular cloning of the chromosomal breakpoints from two NHL cases with t(3;14). Illustrated are the maps of two representative phage clones spanning the breakpoint regions in case SM1444 (SM-71) and KC1445 (KC-51). Chromosome 14 portions of the phage inserts are indicated by a solid line with hatched and black boxes representing switch sequences and C_μ exons, respectively. Vertical arrows point to the junctions of chromosome 3 and 14 sequences. The probes used for Southern (Figure 4) and Northern (Figure 5) analysis are illustrated below the SM-71 map. Restriction enzyme sites are indicated as: B=BamHI; H=HindIII; R=EcoRI; G=BblII; S=sacI.
- Figur 3: Localization of phage SM-71 sequences to chromosomes 3 and 14 by fluorescence

in situ hybridization. Consistent hybridization signals at 3q27 (arrow in panel A) and 14q32 (arrow in panel B) demonstrated that the insert is derived from the translocation junction.

Figures 4A-4C: Southern blot hybridization analysis of bcl-6 rearrangements in NHL carrying 3q27 breakpoints. The probes used are illustrated in Figure 2. U937 and SK-N-MC DNAs are used as germ-line controls since their hybridization pattern was identical to the one observed in a panel of 19 control DNAs tested. The detected cytogenetic abnormalities affecting 3q27 in each case are: KC1445: t(3;14)(q27;q32); SM1444: t(3;14)(q27;q32); TF1403: t(3;14)(q27;q32); LD1411: t(3;14)(q27;q32); EM352: t(3;22)(q27;q11); CF755: t(3;12)(q27;q11); S0955:der(3)t(3;5)(q27;q31).

Figure 5: Identification of the bcl-6 transcriptional unit. 15 µg of total RNA isolated from the indicated human cell lines was analyzed by Northern blot hybridization using the Sac 4.0 probe (see Figure 2). CB33:EBV-immortalized human B lymphoblastoid cell line; HeLa: human cervical carcinoma cell line; Daudi: human Burkitt lymphoma cell line; Hut78: human T-cell leukemia cell line. Hybridization of the same filter to a mouse GAPDH probe is shown as control

for RNA amount loaded in each lane. The faint band comigrating with 28S RNA in all the lanes may be the result of cross-hybridization with ribosomal RNA sequences.

5

Figure 6:

10

15

20

25

Figure 7: pSac 40 plasmid construction.

Figure 8: pGB31 and pGB3s plasmid construction.

30

Figures 9A-9D: cDNA and Amino Acid Sequences of BCL-6 (SEQ ID NOS. 1 and 2). The Sac 4.0 probe was used to screen a recombinant phage cDNA library constructed from Bjab B cell lymphoma line RNA. A 4.0 kilobase cDNA was isolated and its nucleotide sequence was determined. It contains a long open reading frame

35

A

inger
lular
(SEQ ID NOS: 3-4)
eins,

Homology of the NH₂-terminal region of BCL-6 to other Krüppel zinc-finger proteins, viral (VA55R), or cellular non-zinc-finger (kelch) proteins. Black background indicates identical residues found four or more times at a given position; grey indicates conserved residues that appear in at least four sequences at a given position. Conserved amino acid substitutions are defined according to

scheme (P, A, G, S, T), (Q, N, E, D),
(H, K, R), (L, I, V, M), and (F, Y, W).
Numbering is with respect to the
methionine initiation codon of each
gene.

Figure 12:

Exon-intron organization of the BCL-6
gene and mapping of breakpoints
detected in DLCL. Coding and non-
coding exons are represented by filled
and empty boxes, respectively. The
position and size of each exon are
approximate and have been determined by
the pattern of hybridization of various
cDNA probes as well as by the presence
of shared restriction sites in the
genomic and cDNA. The putative first,
second and third exons have been
sequenced in the portions overlapping
the cloned cDNA sequences. The
transcription initiation site has not
been mapped (shaded box on 5' side of
first exon). Patient codes (e.e. NC11,
891546 etc.) are grouped according to
the rearranged patterns displayed by
tumor samples. Arrows indicate the
breakpoint position for each sample as
determined by restriction
enzyme/hybridization analysis. For
samples KC1445 and SM1444, the
breakpoints have been cloned and the
precise positions are known.
Restriction sites marked by asterisks
have been only partially mapped within
the BCL-6 locus. Restriction enzyme
symbols are: S, Sac I; B, Bam HI; X,
Xba I; H, Hind III; R, Eco RI; G, Bgl

II; P, Pst I; Sc, Sca I; St, Stu I; Rs, Rsa I. Tumor samples were collected and analyzed for histopathology at Memorial Sloan-Kettering Cancer Center or at Columbia University.

Figures 13A-13B:

Rearrangements of the BCL-6 gene in diffuse large-cell lymphomas (DLCL). Genomic DNA extracted from tumor biopsies of DLCL cases and from normal lymphocytes (lane N) was digested with the indicated restriction enzymes and analyzed by Southern blot hybridization using the Sac 4.0 probe. Abnormal restriction fragments are indicated by the arrows.

Figures 14A-14C:

Analysis of BCL-6 rearrangements in AIDS-NHL (Figures 14A-14C). DNAs were digested with BamHI (Figure 14A) or XbaI (Figures 14B and 14C) and hybridized to probes Sac4.0 (Figures 14A and 14B) or Sac0.8 (Figure 14C). The BCL-6 germline bands detected by BamHI (11.4 Kb) and XbaI (14 Kb) are indicated. U937 was used as a BCL-6 germline control. Among the cases shown, rearrangements were detected in cases DK782, DK827, and DS16, represented by AIDS-DLCL.

Figure 15:

Restriction map of the germline BCL-6 locus. Exon-intron organization of the BCL-6 gene. Coding and noncoding exons are represented by filled and empty boxes, respectively. The transcription

initiation site has not been mapped (shaded box on 5' side of first exon). The breakpoints detected in AIDS-NHL are indicated by arrows. Restriction enzyme symbols are: S, *SacI*; B, *BamHI*; X, *XbaI*; R, *EcoRI*. RE, restriction enzyme.

Figures 16A-16C:

10

15

20

25

30

35

Analysis of EBV infection (Figure 16A), c-MYC rearrangements (Figure 16B), and p53 mutations (Figure 16C) in AIDS-NHL. Figure 16A: Analysis of EBV termini heterogeneity in AIDS-NHL. DNAs were digested with *BamHI* and subjected to Southern hybridization using a DNA probe specific for the fused termini of the EBV genome. U937, a monocytic leukemia cell line, is used as a negative control. A lymphoblastoid cell line derived by EBV infection of normal polyclonal B cells (NC2) is used as control for polymorphic EBV termini. Representative samples of AIDS-NHL, both positive (DK3794, DK4338, DK2814, DK3973) and negative (DK3479), are shown. Figure 16B: Southern blot analysis of c-MYC rearrangements in AIDS-NHL. Genomic DNAs from the cases shown was digested with *HindIII* and probed with clone MC413RC⁴¹, representative of c-MYC exon 3. A lymphoblastoid cell line (NC2) was used as control for c-MYC germline configuration. Among the cases shown, two cases of AIDS-DLCL (DK3537 and DK1446) display a c-MYC rearrangement.

Figure 16C: Analysis by PCR-SSCP of the p53 gene in AIDS-NHL. Representative examples are shown for p53 exon 5. Samples were scored as abnormal when differing from the normal control (N). A sample known to harbor a p53 mutation was used as positive control (POS). Among the cases shown, DK1171, a case of AIDS-SNCCL, shows a p53 mutation which was further characterized by direct sequencing of the PCR product.

Figures 17A-17B:

Southern blot analysis of the BCL-6 gene configuration in diffuse large cell lymphomas. Genomic DNA extracted from tumor biopsies was digested with the indicated restriction endonucleases and hybridized using the Sac4.0 probe (19). Rearranged fragments are indicated by the arrows. N = normal control DNA obtained from human lymphocytes.

Figures 18A-18B:

Figure 18A: Freedom from progression in BCL-6 rearranged cases (open circles, top curve) compared to BCL-6 germline cases (closed circles, bottom curve) ($P=0.007$). Figure 18B: Overall survival from time of diagnosis for BCL-6 rearranged CLLC (open circle, top curve), compared to BCL-6 germline, BCL-2 germline DLLC (dark triangles, middle curve), and BCL-2 rearranged DLLC (dark boxes, bottom curve) ($P=0.02$).

DETAILED DESCRIPTION OF THE INVENTION

5 The following standard abbreviations are used throughout the specification to indicate specific nucleotides:

C=cytosine	A=adenosine
T=thymidine	G=guanosine

10 This invention provides an isolated vertebrate nucleic acid molecule of the bcl-6 locus. As used herein, bcl-6 locus means the breakpoint cluster region in B-cell lymphomas. The bcl-6 locus is of 30 kilobase in length
15 containing at least a bcl-6 gene which codes for a protein. Therefore, the bcl-6 locus contains both the 5' and 3' flanking region of the coding sequences of the bcl-6 gene.

20 In an embodiment, the isolated, vertebrate nucleic acid molecule of bcl-6 locus is DNA. In another embodiment, the isolated, vertebrate nucleic acid of the bcl-6 locus is cDNA. In a further embodiment, the isolated, vertebrate nucleic acid is genomic DNA. In a still
25 further embodiment, the isolated, vertebrate nucleic acid molecule is RNA.

This invention provides an isolated, human nucleic acid molecule comprising the bcl-6 locus.

30 The DNA molecules described and claimed herein are useful for the information which they provide concerning the amino acid sequence of the polypeptide and as products for the large scale synthesis of the
35 polypeptide by a variety of recombinant techniques. The molecule is useful for generating new cloning and expression vectors, transformed and transfect d

prokaryotic and eukaryotic host cells, and new and useful methods for cultured growth of such host cells capable of expression of the polypeptide and related products.

5

Moreover, the isolated vertebrate nucleic acid molecules are useful for the development of probes to study B cell lymphomas.

10

This invention provides a nucleic acid molecule comprising a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a sequence included within the sequence of the bcl-6 locus. In an embodiment, this molecule is DNA. In

15

another embodiment, the molecule is RNA.

As used herein, the phrase "specifically hybridizing" means the ability of a nucleic acid molecule to recognize a nucleic acid sequence complementary to its own and to form double-helical segments through hydrogen bonding between complementary base pairs.

20

The above nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a sequence of bcl-6 locus may be used as a probe for bcl-6 sequences. Nucleic acid probe technology is well known to those skilled in the art who will readily appreciate that such probes may vary greatly in length and may be labeled with a detectable label, such as a radioisotope or fluorescent dye, to facilitate detection of the probe. DNA probe molecules may be produced by insertion of a DNA molecule having the full-length or a fragment of the bcl-6 locus into suitable vectors, such as plasmids or bacteriophages, followed by transforming into suitable bacterial host cells, replication in the transformed bacterial host cells and harvesting of the DNA probes, using methods

30

35

well known in the art. Alternatively, probes may be generated chemically from DNA synthesizers.

5 RNA probes may be generated by inserting the full length or a fragment of the bcl-6 locus downstream of a bacteriophage promoter such as T3, T7 or SP6. Large amounts of RNA probe may be produced by incubating the labeled nucleotides with a linearized bcl-6 or its fragment where it contains an upstream promoter in the presence of the appropriate RNA polymerase.

10 This invention provides an cDNA molecule of bcl-6 locus operatively linked to a promoter of RNA transcription.

15 This invention provides a vector which comprises the nucleic acid molecule of bcl-6 locus. This invention provides the above vector, wherein the isolated nucleic acid molecule is linked to a plasmid.

20 This invention further provides isolated cDNA molecule of the bcl-6 locus operatively linked to a promoter of RNA transcription. Various vectors including plasmid vectors, cosmid vectors, bacteriophage vectors and other viruses are well known to ordinary skilled practitioners.

25 As an example to obtain these vectors, insert and vector DNA can both be exposed to a restriction enzyme to create complementary ends on both molecules which base pair with each other and are then ligated together with DNA ligase. Alternatively, linkers can be ligated to the insert DNA which correspond to a restriction site in the vector DNA, which is then digested with the restriction enzyme which cuts at that site. Other means are also available and known to an ordinary skilled practitioner.

In an embodiment, a partial cDNA molecule of the bcl-6 locus is linked to pGEM-7zf(-) and the resulting plasmid is designated as pGB31 (Figure 8). Plasmid, pGB31 was deposited on June 3, 1993 with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganism for the Purposes of Patent Procedure. Plasmid, pGB31 was accorded with ATCC Accession Number 75476.

In an another embodiment, a partial cDNA molecule of the bcl-6 locus is linked to pGEM-7zf(-) and the resulting plasmid is designated as pGB3s (Figure 8). Plasmid, pGB3s was deposited on June 3, 1993 with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganism for the Purposes of Patent Procedure. Plasmid, pGB3s was accorded with ATCC Accession Number 75477.

This invention provides a host vector system for the production of a polypeptide encoded by bcl-6 locus, which comprises the above vector in a suitable host.

This invention provides the above host vector system, wherein the suitable host is a bacterial cell, insect cell, or animal cell.

Regulatory elements required for expression include promoter sequences to bind RNA polymerase and transcription initiation sequences for ribosome binding. For example, a bacterial expression vector includes a promoter such as the lac promoter and for transcription initiation the Shine-Dalgarno sequence and the start codon AUG. Similarly, a eukaryotic

expression vector includes a heterologous or homologous promoter for RNA polymerase II, a downstream polyadenylation signal, the start codon AUG, and a termination codon for detachment of the ribosome. Such
5 vectors may be obtained commercially or assembled from the sequences described by methods well-known in the art, for example the methods described above for constructing vectors in general. Expression vectors are useful to produce cells that express the
10 polypeptide encoded by the bcl-6 locus.

This invention further provides an isolated DNA or cDNA molecule described hereinabove wherein the host cell is selected from the group consisting of bacterial cells
15 (such as E.coli), yeast cells, fungal cells, insect cells and animal cells. Suitable animal cells include, but are not limited to Vero cells, HeLa cells, Cos cells, CV1 cells and various primary mammalian cells.

20 This invention provides a method of producing a polypeptide encoded by bcl-6 locus, which comprises growing the above host vector system under suitable conditions permitting production of the polypeptide and recovering the polypeptide so produced.

25 This invention provides a polypeptide encoded by the isolated vertebrate nucleic acid molecule of bcl-6 locus.

30 This invention provides an antibody capable of binding to polypeptide encoded by bcl-6 locus. In an embodiment, the antibody is monoclonal.

This invention provides a method to select specific
35 regions on the polypeptide encoded by the bcl-6 locus to generate antibodies. The protein sequence may be determined from the cDNA sequence. Amino acid

sequences may be analyzed by methods well known to those skilled in the art to determine whether they produce hydrophobic or hydrophilic regions in the proteins which they build. In the case of cell membrane proteins, hydrophobic regions are well known to form the part of the protein that is inserted into the lipid bilayer of the cell membrane, while hydrophilic regions are located on the cell surface, in an aqueous environment. Usually, the hydrophilic regions will be more immunogenic than the hydrophobic regions. Therefore the hydrophilic amino acid sequences may be selected and used to generate antibodies specific to polypeptide encoded by the bcl-6 locus. The selected peptides may be prepared using commercially available machines. As an alternative, DNA, such as a cDNA or a fragment thereof, may be cloned and expressed and the resulting polypeptide recovered and used as an immunogen.

Polyclonal antibodies against these peptides may be produced by immunizing animals using the selected peptides. Monoclonal antibodies are prepared using hybridoma technology by fusing antibody producing B cells from immunized animals with myeloma cells and selecting the resulting hybridoma cell line producing the desired antibody. Alternatively, monoclonal antibodies may be produced by in vitro techniques known to a person of ordinary skill in the art. These antibodies are useful to detect the expression of polypeptide encoded by the bcl-6 locus in living animals, in humans, or in biological tissues or fluids isolated from animals or humans.

The antibody may be labelled with a detectable marker, including but not limited to: a radioactive label, or a calorimetric, luminescent, or fluorescent mark r, or gold. Radioactive labels include but are not limited

to: ^3H , ^{14}C , ^{32}P , ^{33}P ; ^{35}S , ^{36}Cl , ^{51}Cr , ^{57}Co , ^{59}Co , ^{59}Fe , ^{90}Y ,
 ^{125}I , ^{131}I , and ^{186}Re . Fluorescent markers include but are
not limited to: fluorescein, rhodamine and auramine.
Methods of producing the polyclonal or monoclonal
5 antibody are known to one of ordinary skill in the art.

Further, the antibody complex may be detected by a
second antibody which may be linked to an enzyme, such
as alkaline phosphatase or horseradish peroxidase.
10 Other enzymes which may be employed are well known to
one of ordinary skill in the art.

This invention provides for the isolated nucleic acid
molecule of bcl-6 that is labelled with a detectable
15 marker. The detectable marker may be a radioactive
label, a calorimetric, luminescent, or a fluorescent
marker. Other detectable markers are known to those
skilled in the art as hereinabove described.

20 This invention provides an antagonist capable of
blocking the expression of the polypeptide encoded by
the isolated nucleic acid molecule of bcl-6. The
antagonist may be a triplex oligonucleotide capable of
hybridizing to nucleic acid molecule bcl-6.

25 This invention provides an antisense molecule capable
of hybridizing to the nucleic acid molecule bcl-6. The
antisense molecule may be DNA or RNA.

30 This invention provides a triplex oligonucleotide
capable of hybridizing with a double stranded DNA
molecule bcl-6.

35 The antisense molecule may be DNA or RNA or variants
thereof (i.e. DNA with a protein backbone). The
present invention extends to the preparation of
antisense nucleotides and ribozymes that may be used to

interfere with the expression of the receptor recognition proteins at the translation of a specific mRNA, either by masking that mRNA with an antisense nucleic acid or cleaving it with a ribozyme.

5

Antisense nucleic acids are DNA or RNA molecules that are complementary to at least a portion of a specific mRNA molecule. In the cell, they hybridize to that mRNA, forming a double stranded molecule. The cell
10 does not translate an mRNA in this double-stranded form. Therefore, antisense nucleic acids interfere with the expression of mRNA into protein. Oligomers of about fifteen nucleotides and molecules that hybridize to the AUG initiation codon will be particularly
15 efficient, since they are easy to synthesize and are likely to pose fewer problems than larger molecules upon introduction to cells.

20

This invention provides a transgenic nonhuman mammal which comprises the isolated nucleic acid molecule bcl-6 introduced into the mammal at an embryonic stage.

25

This invention provides an assay for non-Hodgkin's lymphoma, comprising (a) incubating a sample of suitable body fluid for a subject with a monoclonal antibody reactive with non-Hodgkin's lymphoma cells to a solid support, (b) removing unbound body fluid from the support, and (c) determining the level of antigen activity exhibited by the bound body fluid to the
30 support.

35

The suitable bodily fluid sample is any bodily fluid sample which would contain non-hodgkin lymphoma cells or fragments thereof. A suitable bodily fluid includes, but is not limited to, serum, plasma, cerebrospinal fluid, and urine. In the preferred embodiment, the suitable bodily fluid sample is serum

or plasma. In addition, the body fluid sample may
cells from bone marrow, or a supernate from a cell
culture. Methods of obtaining a suitable bodily fluid
sample from a subject are known to those skilled in the
art.

This invention provides a method for screening putative
therapeutic agents for treatment of non-Hodgkin's
lymphoma, which comprises determining in a first sample
from a subject with non-Hodgkin's lymphoma the presence
of the isolated nucleic acid molecule bcl-6,
administering to the subject a therapeutic amount of
the agent such that the agent is contacted with the
cell associated with the condition, determining after
a suitable period the amount of the isolated nucleic
acid molecule in a sample from the treated subject, and
comparing the amount of isolated nucleic acid molecule
determined in the first sample with the amount
determined in the sample from the treated subject, a
difference indicating the effectiveness of the agent,
thereby screening putative therapeutic agents for
treatment of non-Hodgkin's lymphoma.

Further, this invention provides an assay system that
is employed to identify drugs or other molecules
capable of binding to the nucleic acid molecule bcl-6
or proteins, either in the cytoplasm or in the nucleus,
thereby inhibiting or potentiating transcriptional
activity. Such assay would be useful in the
development of drugs that would be specific against
particular cellular activity, or that would potentiate
such activity, in time or in level of activity.

The above described probes are also useful for in-situ
hybridization or in order to locate tissues which
express this gene, or for other hybridization assays
for the presence of this gene or its mRNA in various

biological tissues.

5 The in-situ hybridization technique using the labelled
nucleic acid molecule bcl-6 is well known in the art.
Essentially, tissue sections are incubated with the
labelled nucleic acid molecule to allow the
hybridization to occur. The molecule will carry a
marker for the detection because it is "labelled", the
amount of the hybrid will be determined based on the
10 detection of the amount of the marker. Further,
immunohistochemical protocols may be employed which are
known to those skilled in the art.

15 This invention provides a method of diagnosing diffuse-
type B-cell lymphoma in a subject which comprises
detecting in a sample from the subject nucleic acid
molecule of bcl-6 locus.

20 This invention provides a method for diagnosing B-cell
lymphoma in a subject comprising: (a) obtaining DNA
sample from the subject; (b) cleave the DNA sample into
fragments; (c) separating the DNA fragments by size
fractionation; (d) hybridizing the DNA fragments with
a nucleic acid molecule comprising a nucleic acid
25 molecule of at least 15 nucleotides capable of
specifically hybridizing with a sequence included
within the sequence of the nucleic acid molecule of the
bcl-6 locus to detect the DNA fragment containing the
bcl-6 sequence; and (e) comparing the detected DNA
30 fragment from step (d) with the DNA fragment from a
known normal subject, the difference in size of the
fragments indicating the occurrence of B-cell lymphoma
in the subject. In a preferred embodiment, the above
diagnostic method is for diffuse-type B-cell lymphomas.

35

A person of ordinary skill in the art will be able to
obtain appropriate DNA sample for diagnosing B-cell

lymphoma in a subject. The DNA sample obtained by the above described method may be cleaved by restriction enzyme. The uses of restriction enzymes to cleave DNA and the conditions to perform such cleavage are well-known in the art.

In an embodiment, the size fractionation in step (c) of the above-described method is effected by a polyacrylamide gel. In another embodiment, the size fractionation is effected by an agarose gel.

This invention also provides the above-described diagnosis method wherein step the nucleic acid molecule in step (d) is labeled with a detectable marker. The detectable marker includes but is not limited to a radiolabelled molecule, a fluorescent molecule, an enzyme, or a ligand.

In a preferred embodiment, the above-described diagnosis method further comprises transferring the DNA fragments into a solid matrix before the hybridization step (d). One example of such solid matrix is nitrocellulose paper.

As an example for the above-described diagnosis method is shown in Figures 4A-4C where different NHL sample are analyzed. More lymphoma cases and their breakpoints are shown in Figure 6.

This invention also provides a method for diagnosing B-cell lymphoma in a subject comprising: (a) obtaining RNA sample from the subject; (b) separating the RNA sample into different species by size fractionation; (c) hybridizing the RNA species with a nucleic acid molecule comprising a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a sequence included within the sequence of the nucleic

acid molecule of the bcl-6 locus to detect the RNA species containing the bcl-6 sequence; and (d) comparing the RNA species obtained from (c) with the RNA species from a known normal subject, the difference in size of the species indicating the occurrence of B-cell lymphoma in the subject.

In an embodiment, the size fractionation in step (b) is effected by a polyacrylamide or agarose gel.

This invention also provides the above-described method where in step (c), the nucleic acid molecule is labeled with a detectable marker. The detectable marker includes but is not limited to a radiolabelled molecule, a fluorescent molecule, an enzyme, or a ligand.

This invention also provides the above-method further comprises transferring the RNA species into a solid matrix before step (c).

This invention also provides various uses of bcl-6 locus/gene and its derivatives. This invention further provides a method for diagnosis of B cell lymphoma and/or diffuse-type B cell lymphoma using bcl-6 DNA probes or synthetic oligonucleotide primers derived from bcl-6 sequences to detect bcl-6 rearrangements/mutations by Southern blotting PCR or other DNA based techniques.

This invention also provides a method of diagnosis of B cell lymphoma and/or diffuse-type B cell lymphoma using bcl-6 DNA probes or synthetic oligonucleotide primers derived from bcl-6 sequences to detect abnormal bcl-6 RNA species by Northern blotting, PCR or other RNA-based techniques.

This invention further provides a method of diagnosis of B cell lymphoma and/or diffuse-type B cell lymphoma using antiserum or monoclonal antibodies directed against the bcl-6 protein product(s).

5

This invention provides a method of treating a subject with non-Hodgkin's lymphoma comprising administering an effective amount of the antisense molecule of the nucleic acid molecule bcl-6 operatively linked to a suitable regulatory element coupled with a therapeutic DNA into a tumor cell of a subject, thereby treating the subject with non-Hodgkin's lymphoma.

10

This invention provides a method of treating a subject with non-Hodgkin's lymphoma, comprising administering an effective amount of the antagonist capable of blocking the expression of the polypeptide encoded by the isolated nucleic acid molecule of bcl-6, and a suitable acceptable carrier, thereby treating the subject with non-Hodgkin's lymphoma.

15

20

Further, as is known to those of ordinary skill in the art effective amounts vary with the type of therapeutic agent. It is known to those of ordinary skill in the art how to determine an effective amount of a suitable therapeutic agent.

25

The preparation of therapeutic compositions which contain polypeptides, analogs or active fragments as active ingredients is well understood in the art. Typically, such compositions are prepared as injectables, either as liquid solutions or suspensions, however, solid forms suitable for solution in, or suspension in, liquid prior to injection can also be prepared. The preparation can also be emulsified. The active therapeutic ingredient is often mixed with excipients which are pharmaceutically acceptable and

30

35

compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof. In addition, if desired, the composition can
5 contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents which enhance the effectiveness of the active ingredient.

10 A polypeptide, analog or active fragment can be formulated into the therapeutic composition as neutralized pharmaceutically acceptable salt forms. Pharmaceutically acceptable salts include the acid
15 addition salts (formed with the free amino groups of the polypeptide or antibody molecule) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed from the free carboxyl groups can also be
20 derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.

25 The subjects contained herein may be a mammal, or more specifically a human, horse, pig, rabbit, dog, monkey, or rodent. In the preferred embodiment the subject is a human.

30 The compositions are administered in a manner compatible with the dosage formulation, and in a therapeutically effective amount. Precise amounts of active ingredient required to be administered depend on
35 the judgment of the practitioner and are peculiar to each individual.

Suitable regimes for initial administration and booster shots are also variable, but are typified by an initial administration followed by repeated doses at one or more hour intervals by a subsequent injection or other administration.

As used herein administration means a method of administering to a subject. Such methods are well known to those skilled in the art and include, but are not limited to, administration topically, parenterally, orally, intravenously, intramuscularly, subcutaneously or by aerosol. Administration of the agent may be effected continuously or intermittently such that the therapeutic agent in the patient is effective to treat a subject with non-hodgkin's lymphoma.

Finally, this invention provides a therapy of B cell lymphoma and/or diffuse-type B cell lymphoma using anti bcl-6 reagents including specific antisense sequences and compounds interfering with bcl-6 functions.

This invention will be better understood from the Experimental Details which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims which follow thereafter.

EXPERIMENTAL DETAIL SECTION I:

Materials and Methods

5 **DNA Extraction and Southern Blot Analysis.** Total genomic DNA was purified from frozen tumor biopsies by cell lysis, proteinase K digestion, "salting-out" purification and ethanol precipitation as previously described (11). Southern blot hybridization analysis
10 was performed in 50% formamide, 3X SSC, 10X dextran sulphate, 5X Denhardt's solution, 0.5% SDS at 37°C for 16 hrs. Filters were washed in 0.2X SSC, 0.5% SDS at 60°C for 2 hrs. DNA probes were ³²P-labelled by the random priming method (12).

15 **DNA Probes.** The following probes were used for Southern blot analysis of Ig gene rearrangements: i) (J_H) probe: 6.6 kb BamHI/HindIII fragment from the human Ig heavy-chain (Ig_H) locus (13); ii) (C_μ) probe:
20 1.3 kb EcoRI fragment containing the first two exons of human C_μ (13).

25 **Genomic Cloning.** Genomic libraries from NHL cases SM1444 and KC1445 were constructed by partial Sau 3A restriction digestion of genomic DNA and ligation of gel-purified 15-20 kb fractions into LambdaGem-11 phage vector (Promega). Library screening was performed by plaque-hybridization using the C_μ probe.

30 **Fluorescence in situ Hybridization Analysis (FISH).** Phage DNA was labelled with biotin-14-dATP by nick translation and hybridized to metaphase spreads from normal human lymphocytes as described (14). To
35 visualize the hybridization signal and the corresponding bands sequentially under the microscope, the slides were stained and counterstained with propidium iodide and 4'6'-diamideno-2-phenylindole

(DAPI), respectively.

5 Northern Blot Hybridization Analysis. RNAs from
several human cell lines were extracted by the
guanidine-isothiocyanate method (15). For Northern
blot analysis, RNA samples were electrophoresed through
0.9% agarose-2.2M formaldehyde gels and then
transferred to nitrocellulose filters. Hybridization
and washing were performed as described for Southern
10 blot analysis.

Experimental Results:

15 DNA was extracted from tumor tissue of two cases
(SM1444 and KC1445) of IgM-producing, diffuse-type B-
cell NHL carrying the t(3;14)(q27;q32) translocation.
Since the involvement of the Ig_H locus was suspected
based on the 14q32 breakpoint, SM1444 and KC1445 DNAs
were first analyzed by Southern blot hybridization
20 using combinations of enzymes and probes specific for
the J_H and C_μ regions of the Ig_H locus (13). In both
cases, digestion by BamHI showed rearranged fragments
containing J_H sequences (Figure 1). Subsequent
hybridizations to the C_μ probe showed, in each case,
25 that one rearranged fragment containing J_H sequences
was not linked to C_μ sequences (see failure of the C_μ
probe to hybridize to the same rearranged BamHI
fragment detected by J_H (Figure 1) as would be expected
for the physiologically rearranged Ig_H allele in IgM
30 producing cells. In addition, in both cases, digestion
with HindIII and hybridization with C_μ detected a
rearranged fragment, a finding inconsistent with either
germ-line or physiologically rearranged Ig_H genes,
since both HindIII sites flanking C_μ sequences are not
35 involved in V-D-J arrangements (13). The observed
pattern is, however, consistent with chromosomal
breakpoints located within C_μ switch sequences, as

previously observed in several cases of chromosomal translocations involving the Ig_H locus (2,16-18).

5 Based on this analysis, the C_μ containing fragments from each case were cloned by screening genomic libraries constructed from SM1444 and KC1445 DNAs using the C_μ probe. Restriction mapping and hybridization analysis of several phage clones led to the
10 identification of recombinant phages from each library which contained C_μ sequences linked to sequences unrelated to the Ig_H locus (see Figure 2 for maps of representative phage clones). The Ig portions of the phage inserts overlapped along the C_μ region extending
15 5' into the switch region where alignment with the restriction map of the normal Ig heavy-chain locus was lost. The location of the breakpoint within C_μ switch sequences was confirmed for case SM1444 by DNA sequence analysis of the breakpoint junction of phage SM-71, which revealed the presence of the repeated motifs
20 typical of the Ig_H switch regions on the chromosome 14 side (19). The Ig -unrelated portions of phage SM-71 and KC-51 also overlapped with each other in their restriction maps, suggesting that they were derived from the same genomic region. This notion is further
25 supported by the fact that probe Sac 4.0 derived from SM-71 was able to hybridize to the corresponding region of KC-51 in Southern blot analysis.

To determine the chromosomal origin of the Ig -unrelated
30 sequences, a recombinant phage (SM-71) derived from case SM1444, was used as a probe in FISH analysis on metaphase chromosome spreads from mitogen-stimulated normal blood lymphocytes. The phage probe hybridized specifically to chromosome 14q32 as well as to
35 chromosome 3q27 (Figure 3), indicating that the recombinant phage insert contained one of the two chromosomal junctions of the reciprocal $t(3;14)$

translocation. Thus, taken together, the results of cloning and FISH analysis established that, in both NHL cases studied, the chromosomal translocation has linked sequences within the switch region of the C_μ locus to sequences from band 3q27, consistent with the cytogenetic description of the t(3;14)(q27;q32) translocation. In the two NHL cases studied, the breakpoints on 3q27 were located within 3 kb of the same genomic locus, which was termed bcl-6.

In order to determine whether 3q27 breakpoints in additional NHL cases were also located within the cloned portion of the bcl-6 locus, bcl-6 rearrangements were examined in a total of 19 NHL cases carrying 3q27 breakpoints, including 4 (two cloned cases and two additional ones) carrying t(3;14)(q27;q32) as well as 15 cases carrying 3q27 translocations involving regions other than 14q32. Southern blot hybridization using probes derived from phage SM-71 (see Figure 2) detected rearranged fragments in EcoRI- and/or BglII-digested DNA in 7 of 19 cases studied, including all 4 t(3;14) cases as well as 3 cases with other types of translocations (see Figures 4A-4C for cytogenetic description of the cases and representative results). These results indicate that heterogeneous 3q27 breakpoints cluster in a fairly restricted region within bcl-6 independently of the partner chromosome involved in the translocation.

Whether the bcl-6 locus adjacent to the chromosomal breakpoints contained a transcriptional unit was investigated. Probe Sac 4.0 (see Figure 2) was used to detect RNA expression in several human cell lines by Northern blot analysis. A major 2.4 kb RNA species was readily detectable in two B-cell derived cell lines tested, while a relatively less abundant 4.4 kb species is present in CB33 only. No hybridization was detected

in a T-cell derived cell line (HUT 78) nor in HeLa cells (Figure 5). This result indicates that 3q27 sequences immediately adjacent to the chromosomal breakpoint cluster are part of a gene (bcl-6) which is expressed in cells of the B lineage.

Experimental Discussion:

This study reports the identification and cloning of a genomic region, bcl-6, involved in recurrent chromosomal translocations affecting band 3q27 in NHL. The region is defined by the clustered position of breakpoints in seven NHL cases carrying 3q27 translocations involving either IgH or several other loci. A more precise definition of the bcl-6 locus and of the frequency of its involvement in NHL requires cloning and characterization of additional bcl-6 sequences and studying additional tumor cases. Nevertheless, the finding that various translocation partner chromosomes have been joined to the same region on chromosome 3 in cytogenetically heterogeneous NHL cases supports the notion that rearrangement of the bcl-6 locus may represent the critical common denominator of translocations involving 3q27.

The second finding of this study is that the bcl-6 locus contains a gene which is expressed in B-cells. It is not clear at this stage whether the chromosomal breakpoints directly truncate coding or regulatory sequences of bcl-6, or, whether the gene remains intact with its regulation overridden by transcriptional control motifs juxtaposed by the translocation. The clustering of breakpoints in the seven studied NHL cases suggests, however, that bcl-6 may be a proto-oncogene which can contribute to NHL pathogenesis upon activation by chromosomal translocation. Results of this study will allow elucidation of the normal

structure and function of the bcl-6 gene in order to understand the pathogen consequences of chromosomal translocation of bcl-6 and its role in lymphomagenesis.

5 REFERENCES FOR SECTION I:

1. Gaidano, G., and Dalla-Favera, R., (1992) Oncogenes and tumor suppressor genes. In: Neoplastic Hematopathology, D.M. Knowles (ed.), Wilkins & Wilkins, pp 245-261.
10
2. Dalla-Favera, R., et al. (1982) Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells, Proc. Natl. Acad. Sci. USA 79:7824-7827.
15
3. Taub, R., et al. (1982) Translocation of c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells, Proc. Natl. Acad. Sci. USA 79:7837-7841.
20
4. Bakhshi, A., et al. (1985) Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around J_H on chromosome 14 and near a transcriptional unit on 18, Cell 41:889-906.
25
5. Tsujimoto, U., et al. (1985) Involvement of the Bcl-2 gene in human follicular lymphoma, Science 228:1440-1443.
30
6. Cleary, M.L., and Sklar, J., (1985) Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18, Proc. Natl. Acad. Sci. USA 82:7439-7444.
35

7. Motokura, T., et al. (1991) A novel cyclin encoded by a bcl-1 linked candidate oncogene, Nature 350:512-514.
- 5 8. Raffeld, M., and Jaffe, E.S., (1991) Bcl-1, t(11;14), and mantle zone lymphomas, Blood 78:259-261.
- 10 9. Offit, K., et al. (1989) t(3;22)(q27;q11): A novel translocation associated with diffuse non-Hodgkin's lymphoma, Blood 74:1876-1879.
- 15 10. Bastard, C., et al. (1992) Translocations involving band 3q37 and Ig gene regions in non-Hodgkin's lymphoma, Blood 79:2527-2531.
- 20 11. Miller, S.A., et al. (1988) A simple salting out procedure for extracting DNA from human nucleated cells, Nucleic Acids Res, 16:1215-1218.
- 25 12. Feinberg, A.P., and Vogelstein, B., (1983) A technique for radiolabelling DNA restriction endonuclease fragments to high specific activity, Anal. Biochem., 132:6-13.
- 30 13. Ravetch, J.V., et al. (1981) Structure of the human immunoglobulin μ locus: characterization of embryonic and rearranged J and D regions, Cell, 27:583-591.
- 35 14. Rao, P.H., et al. (1994) Subregional localization of 20 single-copy loci to chromosome 6 by fluorescence in situ hybridization, Cyto. and Cell Genetics 66:272-273.
15. Chirgwin, J.M., et al. (1979) Isolation of biologically active ribonucleic acid from sources

enriched in ribonuclease, Biochemistry, 18:5294-5299.

- 5 16. Peschle, C., et al. (1984) Translocation and rearrangement of c-myc into immunoglobulin alpha heavy chain locus in primary cells from acute lymphocytic leukemia, Proc. Natl. Acad. Sci. U.S.A., 81:5514-5518.
- 10 17. Showe, L.C., et al. (1985) Cloning and sequencing of a c-myc oncogene in a Burkitt's lymphoma cell line that is translocated to a germ line alpha switch region, Mol. Cell. Biol., 5:501-509.
- 15 18. Neri, A., Barriga, et al. (1988) Different regions of the immunoglobulin heavy chain locus are involved in chromosomal translocations in distinct pathogenic forms of Burkitt lymphoma, Proc. Natl. Acad. Sci. USA, 85:2748-2752.
- 20 19. Rabbits, T.H., et al. (1991) Human immunoglobulin heavy chain genes: evolutionary comparisons of C mu, C delta and C gamma genes and associated switch sequences, Nucleic Acids Res., 9:4509-4524.
- 25 20. Schmid, et al. (1991) Nature, 332:733.

EXPERIMENTAL DETAIL SECTION II

Introduction:

5 The molecular analysis of specific chromosomal
translocations has improved the understanding of the
pathogenesis of non-Hodgkin lymphoma (NHL), a
heterogeneous group of B-cell or, less frequently, T-
cell malignancies (1,2). The (14;18) chromosomal
10 translocation, which causes the deregulated expression
of the anti-apoptosis gene BCL-2, plays a critical role
in the development of follicular lymphoma (FL) (3-6),
which accounts for 20 to 30% of all NHL diagnoses (7).
Burkitt's lymphoma (BL) and mantle-cell lymphoma, two
15 relatively rare NHL types, are characterized by
chromosomal translocations causing the deregulated
expression of the cell-cycle progression genes C-MYC
and the BCL-1/cyclin D1, respectively (8-15).

20 Relatively little is known about the molecular
pathogenesis of diffuse large cell lymphoma (DLCL), the
most frequent and most lethal human lymphoma (7). DLCL
accounts for ~40% of initial NHL diagnoses and is often
the final stage of progression of FL(7). A small
25 percentage of DLCL display C-MYC rearrangements (16)
and 20 to 30% display alterations of BCL-2 reflecting
the tumor's derivation from FL (17). However, no
consistent molecular alteration has been identified
that is specific for DLCL.

30 Chromosomal translocations involving reciprocal
recombinations between band 3q27 and several other
chromosomal sites are found in 8 to 12% of NHL cases,
particularly in DLCL (18-19). From NHL samples
35 displaying recombinations between 3q27 and the
immunoglobulin (Ig) heavy chain locus on 14q32, the
chromosomal junctions of several (3;14)(q27;q32)

translocations were cloned and identified a cluster of breakpoints at a 3q27 locus named BCL-6.

Experimental Results:

5 To isolate normal BCL-6 cDNA, a cDNA library constructed from the NHL cell line Bjab (22) was screened with a probe (20-21) derived from the chromosomal region flanking the breakpoints of two
10 t(3;14)(q27;32) cases. A phage cDNA library constructed from RNA of the Bjab lymphoma cell line was screened (1×10^6 plaques) by plaque hybridization with the Sac 4.0 probe that had been ^{32}P -labelled by random priming (22). Sequence analysis (Figures 10A-10B)
15 revealed that the longest clone (3549 bp), approximately the same size as BCL-6 RNA, codes for a protein of 706 amino acids with a predicted molecular mass of 79kD. The putative ATG initiation codon at position 328 is surrounded by a Kozak consensus
20 sequence (23) and is preceded by three upstream in-frame stop codons. The 1101-bp 3'-untranslated region contains a polyadenylation signal followed by a track of poly(A). These features are consistent with BCL-6 being a functional gene.

25 The NH_2 - and COOH - termini of the BCL-6 protein (Figures 10A-10B) have homologies with "zinc-finger" transcription factors (24). BCL-6 contains six C_2H_2 zinc-finger motifs (Figure 10A) and a conserved stretch
30 of six amino acids (the H/C link) connecting the successive zinc-finger repeats (25). BCL-6 can be assigned to the Krüppel-like subfamily of zinc-finger proteins. The NH_2 - terminal region of BCL-6 is devoid of the FAX (27) and KRAB (28) domains sometimes seen in
35 Krüppel-related zinc-finger proteins, but it does have homologies (Figure 11) with other zinc-finger transcription factors including the human ZFPJS

protein, a putative human transcription factor that regulates the major histocompatibility complex II promoter, the Tramtrack (ttk) and Broad-complex (Br-c) proteins in *Drosophila* that regulate developmental transcription (29), the human KUP protein (31), and the human PLZF protein, which is occasionally involved in chromosomal translocations in human promyelocytic leukemia (32). The regions of NH₂-terminal homology among ZFPJS, ttk, Br-c, PLZF and BCL-6 also share some degree of homology with viral proteins (e.g. VA55R) of the poxvirus family (33) as well as with the *Drosophila* kelch protein involved in nurse cell-oocyte interaction (34). These structural homologies suggest that BCL-6 may function as a DNA-binding transcription factor that regulates organ development and tissue differentiation.

The cDNA clone was used as a probe to investigate BCL-6 RNA expression in a variety of human cell lines by Northern blot analysis. A single 3.8 kb RNA species was readily detected (Figure 11) in cell lines derived from mature B-cells, but not from pro-B-cells or plasma cells, T cells or other hematopoietic cell lineages. The BCL-6 RNA was not detectable in other normal other tissues, except for skeletal muscle in which low level expression was seen. Thus, the expression of BCL-6 was detected in B-cells at a differentiation stage corresponding to that of DLCL cells. This selective expression in a 'window' of B-cell differentiation suggests that BCL-6 plays a role in the control of normal B-cell differentiation and lymphoid organ development.

To characterize the BCL-6 genomic locus, the same cDNA probe to screen a genomic library from human placenta was used. A phage genomic library constructed from normal human placenta DNA (Stratagene) was screened (8×10^5 plaques) with the BCL-6 cDNA. Twelve overlapping

clones spanning ~50kb of genomic DNA were isolated. After restriction mapping, the position of various BCL-6 exons was determined by Southern hybridization using various cDNA probes. By restriction mapping, hybridization with various cDNA probes, and limited nucleotide sequencing, the BCL-6 gene was found to contain at least ten exons spanning ~26 kb of DNA (Figure 12). Sequence analysis of the first and second exons indicated that they are noncoding and that the translation initiation codon is within the third exon.

Various cDNA and genomic probes were used in Southern (DNA) blot hybridizations to determine the relationship between 3q27 (Table 1). Monoallelic rearrangements of BCL-6 were detected in 12 of 17 tumors by using combinations of restriction enzymes (Bam HI and Xba I) and probe which explore ~16 kb within the BCL-6 locus. These 12 positive cases carry recombinations between 3q27 and several different chromosomes (Table 1), indicating that heterogeneous 3q27 breakpoints cluster in a restricted genomic locus irrespective of the partner chromosome involved in the translocation. Some DLCL samples (5 of 17) do not display BCL-6 rearrangements despite cytogenetic alterations in band 3q27, suggesting that another gene is involved or, more likely, that there are other breakpoint clusters 5' or 3' to BCL-6. If the latter is true, the observed frequency of BCL-6 involvement in DLCL (33%, see below) may be an underestimate.

Table 1.

Frequency of BCL-6 rearrangements in DLCL carrying chromosomal translocations affecting band 3q27

5	Translocation	Fraction of tumors with BCL-6 rearrangements
	t(3;14)(q27;q32)	4/4
10	t(3;22)(q27;q11)	2/3
	t(3;12)(q27;q11)	1/1
	t(3;11)(q27;q13)	1/1
	t(3;9)(q27;p13)	0/1
	t(3;12)(q27;q24)	0/1
15	der(3)t(3;5)(q27;q31)	1/1
	t(1;3)(q21;q27)	1/1
	t(2;3)(q23;q27)	1/1
	der(3)t(3;?)(q27;?)	1/3
20	Tumor samples listed in the Table were collected and analyzed for histopathology and cytogenetics at Memorial Sloan-Kettering Cancer Center.	
25	A panel of tumors not previously selected on the basis of 3q27 breakpoints but representative of the major subtypes of NHL as well as of other lymphoproliferative diseases was analyzed. Similar rearrangements were detected in 13 of 39 DLCL, but not in other cases including other NHL subtypes (28 FL, 20 BL, and 8 small lymphocytic NHL), acute lymphoblastic leukemia (ALL; 21 cases), and chronic lymphocytic leukemia (CLL; 31). These findings indicate that BCL-6 rearrangements are specific for and frequent in DLCL. In addition, the frequency of rearrangements in DLCL (33%) significantly exceeds that (8 to 12%) reported at the cytogenetic level, suggesting that some of the observed rearrangements may involve submicroscopic chromosomal alterations undetectable at the cytogenetic level.	
30		
35		

All the breakpoints in BCL-6 mapped to the putative 5' flanking region, the first exon or the first intron (Figure 12). For two patients that carry (3;12)(q27;q32) translocations, the chromosomal breakpoints have been cloned and precisely mapped to the first intron (SM1444) or to 5' flanking sequences (KC1445) of BCL-6 on 3q27, and to the switch region of IgH on 14q32 (20-21). In all rearrangements, the coding region of BCL-6 was left intact whereas the 5' regulatory region, presumably containing the promoter sequences, was either completely removed or truncated. The resultant fusion of BCL-6 coding sequences to heterologous (from other chromosomes) or alternative (within the BCL-6 locus) regulatory sequences may disrupt the gene's normal expression pattern. A BCL-6 transcript of normal size was detected by Northern blot analysis of DLCL cells carrying either normal or truncated BCL-6. Some of the truncations were in the 5' flanking sequences and would therefore not be expected to generate structurally abnormal transcripts.

Experimental Discussion:

Zinc-finger encoding genes are candidate oncogenes as they have been shown to participate in the control of cell proliferation, differentiation, and organ pattern formation (24). In fact, alterations of zinc-finger genes have been detected in a variety of tumor types. These genes include PLZF (32) and PML (35-38) in acute promyelocytic leukemia, EVI-1 (38-39) in mouse and human myeloid leukemia, TTG-1 (40) in T-cell CLL, HTRX (41-43) in acute mixed-lineage leukemia, and WT-1 (44) in Wilm's tumor. Terminal differentiation of hematopoietic cells is associated with the down-regulation of many Krüppel-type zinc-finger genes. Thus, constitutive expression of BCL-6, caused by chromosomal rearrangements, interferes with normal B-

cell differentiation, thereby contributing to the abnormal lymph node architecture typifying DLCL.

5 Given that DLCL accounts for ~80% of NHL mortality (7),
the identification of a specific pathogenetic lesion
has important clinicopathologic implications. Lesions
in BCL-6 may help in identifying prognostically
distinct subgroups of DLCL. In addition, since a
therapeutic response can now be obtained in a
10 substantial fraction of cases (7), a genetic marker
specific for the malignant clone may be a critical tool
for the monitoring of minimal residual disease and
early diagnosis of relapse (45).

15 The gene cloned from chromosomal translocations
affecting band 3q27, which are common in DLCL codes for
a 79 kD protein that is homologous with zinc-finger
transcription factors. In 33% (13/39) of DLCL samples,
but no in other types of lymphoid malignancies, the
20 BCL-6 gene is truncated within its 5' noncoding
sequences, suggesting that its expression is
deregulated. Thus, BCL-6 is a proto-oncogene
specifically involved in the pathogenesis of DLCL.

25 REFERENCES FOR SECTION II:

1. Chaganti, R.S.K., et al. (1989) Molecular
Diagnostics of Human Cancer, pp. 33-36.
- 30 2. Nathwani, B.N., (1992) Neoplastic Hemopathology,
pp. 555-601.
3. Tsujimoto, Y., et al. (1985) Science 228:1440.
- 35 4. Cleary, M.L. and Sklar, J., (1985) Proc. Natl.
Acad. Sci. U.S.A. 82:7439.

5. Bakshi, A., et al. (1985) Cell 41:899.
6. Korsmeyer, S.J., (1992) Blood 80:879.
- 5 7. Magrath, I.T., (1990) The Non-Hodgkin's Lymphomas
pp. 1-14.
8. Dalla-Favera, R., et al. (1982) Proc. Natl. Acad. Sci. U.S.A. 79:7824.
- 10 9. Taub, R., et al. (1982) Proc. Natl. Acad. Sci. U.S.A. 79:7837.
- 15 10. Dalla-Favera, R., (1993) Causes and Consequences of Chromosomal Translocations pp. 313-321.
11. Tsujimoto, Y., et al. (1985) Nature 315:340.
12. Meeker, T.C., et al. (1989) Blood 74:1801.
- 20 13. Motokura, T., et al. (1991) Nature 350:512.
14. Williams, M.E., et al. (1991) Blood 78:493.
- 25 15. Raffeld, M., and Jaffe, E., (1991) Blood 78:259.
16. Ladanyi, M., et al. (1991) Blood 77:1057.
17. Offit, K., et al. (1989) Bri. J. Haematol. 72:178.
- 30 18. Offit, K., et al. (1989) Blood 74:1876.
19. Bastard, C., et al. (1992) Blood 79:2527.
- 35 20. Ye, B.H., et al. (1993) Cancer Res 53:2732.
21. Baron, B.W., et al. (1993) Proc. Natl. Acad. Sci.

U.S.A. 90:5262.

22. Feinbert, A.P., and Vogelstein, B., (1983) Anal. Biochem. 132:6.

5

23. Kozak, M., (1989) J. Cell. Biol 108:229.

24. El-Baradi, T., and Pieler, T., (1991) Mech. Dev 35:155.

10

25. Rosenbert, U.B., et al. (1989) Nature 319:336.

26. Bellefroid, E.J., et al. (1989) DNA 8:377.

15

27. Knochel, W., et al. (1989) Proc. Natl. Acad. Sci. U.S.A. 86:6097.

28. Bellefroid, E.J., et al. (1991) DNA 88:3608.

20

29. Harrison, S.D., and Travers, A.A., (1990) EMBO J. 9:207.

30. DiBello, R.R., et al. (1991) Genetics 129:385.

25

31. Chardin, P., et al. (1991) Nucleic Acid Res. 19:1431.

32. Chen, Z., et al. (1993) EMBO J. 12:1161.

30

33. Koonin, E.V., et al. (1992) Trends Biochem. Sci. 17:213.

34. Xue, F., and Cooley, L., (1993) Cell 72:681.

35

35. de Thé, H., et al. (1991) Cell 66:675.

36. Kazizuka, A., et al. (1991) Cell 66:663.

37. Pandolfi, P.P., et al. (1991) Oncogene 6:1285.
38. Morishita, K., et al. (1988) Cell 54:831.
- 5 39. Fichelson, S., et al. (1992) Leukemia 6:93.
40. McGuire, E.A., et al. (1989) Cell Biol. 9:2124.
41. Djabali, M., et al. (1992) Nature Genet. 2:113.
- 10 42. Tkachuk, D.C., et al. (1992) Cell 71:691.
43. Gu, Y., et al. (1992) Cell 71:701.
- 15 44. Haber, D.A., et al. (1990) Cell 61:1257.
45. Medeiros, L.J., et al. (1992) Neoplastic Hemopathology, pp. 263-298.

EXPERIMENTAL DETAIL SECTION III

Introduction:

5 Non Hodgkin's lymphoma (NHL), the most frequent tumor
occurring in patients between the ages of 20 and 40,
includes several distinct clinico-pathologic subtypes,
among which diffuse lymphoma with a large cell
component (DLCL) is the most clinically relevant in
10 terms of morbidity and mortality (1). DLCL include
intermediate-grade lymphomas with pure diffuse large-
(DLCL), or mixed small- and large-cell (MX-D)
histology, as well as high-grade immunoblastic (IMB)
lymphoma. These tumors can occur "de novo",
15 accounting for 30-40% of initial NHL diagnosis and, in
addition, can represent the final "transformation"
stage of follicular lymphomas (FL), small lymphocytic
lymphoma and chronic lymphocytic leukemia. Considered
together, "de novo" and "post-transformation" DLCL
20 account for up to 80% of NHL mortality (1).

During the past decade, abnormalities involving proto-
oncogenes and tumor suppressor genes have been
identified in association with distinct NHL subtypes
25 (2). These genetic lesions represent important steps
in lymphomagenesis as well as tumor-specific markers
which have been exploited for diagnostic and prognostic
purposes (3,4). Examples include alterations of the
MYC oncogene in Burkitt lymphoma (BL), and of the BCL-2
30 and BCL-1 oncogenes in FL and mantle-cell NHL,
respectively. With respect to DLCL, several molecular
alterations have been detected at variable frequency,
but none has been specifically or consistently
associated with the disease (2). In this invention the
35 frequency and disease-specificity of BCL-6 (5-10)
rearrangements among the principal categories of
lymphoproliferative disease, including different NHL

subtypes, acute and chronic lymphoid leukemias and multiple myeloma is demonstrated.

Materials and Methods:

5

Samples of lymphnode biopsies, bone marrow aspirates and peripheral blood were collected by standard diagnostic procedures during the course of routine clinical evaluation in the Division of Surgical Pathology, Department of Pathology, Columbia University. In all instances, the specimens were collected before specific anti-tumor treatment. Diagnoses were based on the results of histopathologic, immunophenotypic and immunogenotypic analysis (11). In all cases, the fraction of malignant cells in the pathologic specimen was at least 70% as determined by cytofluorimetric or immunohistochemical analysis of cell-surface markers or antigen receptor (immunoglobulin heavy chain and T cell receptor β chain) gene rearrangement analysis (11).

10
15
20

Genomic DNA was prepared from diagnostic specimens by cell lysis, proteinase K digestion, phenol-chloroform extraction and ethanol precipitation. For Southern blot analysis, 6 μ g of DNA were digested with the appropriate restriction endonuclease, electrophoresed in a 0.8% agarose gel, denatured, neutralized and transferred to Duralose filters (Stratagene, La Jolla, CA). Filters were then hybridized with the BCL-6-specific Sac 4.0 probe (10) that had been 32 P-labelled by the random priming technique. After hybridization, filters were washed in 0.2X SSC (1X SSC = 0.15 M NaCl + 0.015 M sodium citrate / 0.5% sodium dodecyl sulfate) for 2 hours at -60°C and then subjected to autoradiography for 24-48 hours at -80°C using intensifying screens.

25

30

35

All NHL cases were also analyzed for rearrangement of the BCL-2 gene using the previously described probes corresponding to the MBR and MCR regions. Immunophenotypic analysis of immunoglobulin and cell surface marker expression was performed as previously described (11).

Comparisons of histologic subsets with or without BCL-6 rearrangement were made utilizing the method of inferences from proportions (12).

Experimental Results:

The tumor panel (Table 2) used for this study is representative of the major categories of lymphoproliferative disease including NHL, 125 cases, ALL 45, CLL 51 and MM 23. The NHL series was representative of low- 41, intermediate- 45 and high-grade 24 subtypes according to the Working Formulation. Fifteen cases of cutaneous T-cell NHL were also included.

The presence of BCL-6 rearrangements was analyzed by Southern blot hybridization of tumor DNAs using a probe (Sac 4.0) (10) and restriction enzymes (BamHI and XbaI) which, in combination, explore a region of 15.2 Kb containing the 5' portion of the BCL-6 gene (first exon, 7.5 Kb of first intron and 7.4 Kb of 5' flanking sequences) (10). This region was previously shown to contain the cluster of breakpoints detected in NHL. No additional rearrangements were found using probes and restriction enzymes exploring approximately 10kb either 5' or 3' to BCL-6 sequences

The results of this analysis are summarized in Table 2 and representatively shown in Figures 13A-13B. All cases of ALL, CLL and MM showed a normal BCL-6 gene.

Eighteen of the 125 NHL cases displayed BCL-6 rearrangements. Among distinct NHL histologic subtypes, rearrangements were detected in 16/45 (35.5%) DLLC and in 2/31 (6.4%) FL ($p < .001$). One of these 2
5 FL cases showed both follicular and diffuse patterns of growth. Among DLLC, rearrangements were significantly more frequent in DLCL (15/33, 45.4%) than in MX-D (1/10, 10%) ($p < .01$), suggesting that these genetic
10 lesions may be specifically associated with the diffuse large cell component of these tumors. All of the DLLC cases displaying BCL-6 rearrangements lacked BCL-2 rearrangements which were found in only two 2 DLLC cases. Although cytogenetic data were not available
15 for the panel of tumors studied, the frequency of BCL-6 rearrangements far exceeds that expected for 3q27 aberrations (10-12% in DLLC) (8, 9), suggesting that BCL-6 rearrangements can occur as a consequence of submicroscopic chromosomal aberrations.

20 In order to determine whether the presence of BCL-6 rearrangements correlated with distinct immunophenotypic features of DLLC, the entire panel was analyzed for expression of immunoglobulin κ and λ light chains, and B cell-associated antigens CD19, CD20 and
25 CD22 (11). As expected, the expression of these markers was variable in the DLLC cases tested. However, no correlation with the BCL-6 rearrangement status was found.

Table 2.

R arrangements f th BCL-6 gen in lymphoid tumors

	TUMOR	HISTOTYPE	REARRANGED/TESTED	%
5	<hr/>			
	<u>NHL</u>			
	Low grade:	SL	0/10	0
		SCC-F	2*/18	11
		MX-F	0/13	0
10	Intermediate grade:			
		MX-D	1/10	10
		DLCL	15/33	45
		SCC-D	0/2	0
15	High grade:			
		IMB	0/2	0
		SNCL	0/22	0
20	Others:	CTCL	0/15	0
	<u>ALL</u>			
		B-lineage:	0/34	0
		T-lineage:	0/11	0
25	<u>CLL</u>	B-lineage:	0/41	0
		T-lineage:	0/10	0
	<u>MM</u>		0/23	0
30	<hr/>			
35	<p>NHL, non-Hodgkin's lymphoma; ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; MM, multiple myeloma; SL, small lymphocytic; SCC-F, follicular small cleaved cell; MX-F, follicular mixed; MX-D, diffuse mixed cell; DLCL, diffuse large cell; SCC-D, diffuse small cleaved cell; IMB, immunoblastic; SNCL, small non-cleaved cell lymphoma; CTCL, cutaneous T-cell lymphoma. *: one case showed follicular and diffuse growth patterns.</p>			

Experimental Discussion:

In this study, BCL-6 rearrangement is established as the most frequent abnormality detectable in DLLC. Previous studies have indicated MYC and BCL-2 rearrangements detectable in 5-20% and 20% of DLLC, respectively (13). Compared to those lesions, which are also commonly associated with Burkitt's lymphoma (MYC) and FL (BCL-2), BCL-6 rearrangements appear to be more disease-specific since they were exclusively found in DLLC with the exception of 2 of 45 FL cases. Considering that one of these two FL cases displayed areas of diffuse histology, it is conceivable that BCL-6 rearrangements may be occasionally associated with atypical FL cases with mixed follicular and diffuse components. The recurrent and specific association between DLLC and structural lesions of a gene coding for a zinc finger-type transcription factor related to several known proto-oncogenes 10 suggests that these abnormalities may play a role in pathogenesis of DLCL.

Among the heterogeneous DLLC spectrum, BCL-6 rearrangements were significantly more frequent in tumors displaying a pure diffuse large cell histology (DLCL) all of which lacked BCL-2 rearrangements. Considering that DLCL can originate both "de novo" and from the "transformation" of FL, and that the latter typically carry BCL-2 rearrangements, results suggest that BCL-6 rearrangements may be specifically involved in the pathogenesis of "de novo" DLLC. This conclusion is consistent with recent findings indicating that other genetic alterations, namely the inactivation of the p53 tumor suppressor gene, may be involved in the transformation of FL to DLLC (14).

The results presented herein have relevant diagnostic and prognostic implications. DLLC represent a

heterogeneous group of neoplasms which are treated homogeneously despite the fact that only 50% of patients experience long-term disease free survival (1). The presence of a marker such as BCL-6 rearrangement identifies a sizable subset of cases with a distinct pathogenesis and, distinct biological behavior.

The pathogenesis of non-Hodgkin lymphoma with a large-cell component (DLCLC, including diffuse large-cell, DLCL, diffuse mixed-cell, MX-D, and immunoblastic, IMB) is unknown. The incidence and disease-specificity of BCL-6 rearrangements in a large panel of lymphoid tumors, including acute and chronic lymphoid leukemias (96 cases), various NHL types (125 cases), and multiple myelomas (23 cases) has been tested. BCL-6 rearrangements were found in 16/45 (35.5%) DLCLC, more frequently in DLCL (15/33, 45%) than in MX-D (1/10, 10%), in 2/31 (6.4%) follicular NHL, and in no other tumor types. BCL-6 rearrangements represent the first genetic lesion specifically and recurrently associated with DLCLC and should prove useful for understanding the pathogenesis as well as for the clinical monitoring of these tumors.

25

REFERENCES FOR SECTION III

1. Magrath, I.T. (1990) The Non-Hodgkin's Lymphomas: An Introduction, The Non-Hodgkin's Lymphomas, Edward Arnold, London, p 1.
2. Gaidano, G., and Dalla-Favera, R. (1993) Biologic and molecular characterization of non-Hodgkin's lymphoma, Curr. Opin. Oncol. 5:776.
3. Gribben, J.G., et al. (1991) Immunologic purging of marrow assessed by PCR before autologous bone

marrow transplantation for B-cell lymphoma, N. Engl. J. Med. 325:1525.

- 5 4. Yunis, J.J., et al. (1989) Bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma, N. Engl. J. Med. 320:1047.
- 10 5. Ye, B.H., et al. (1993) Cloning of bcl-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma, Cancer Res. 53:2732.
- 15 6. Baron, B.W., et al. (1993) Identification of the gene associated with the recurring chromosomal translocations t(3;14)(q27;q32) and t(3;22)(q27;q11) in B-cell lymphomas, Proc. Natl. Acad. Sci. USA 90: 5262.
- 20 7. Kerckaert, J.P., et al. (1993) LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas, Nature Genet. 5:66.
- 25 8. Offit, K, et al. (1989) t(3;22 (q27;q11): A novel translocation associated with diffuse non-Hodgkin's lymphoma, Blood 74: 1876.
- 30 9. Bastard, C, et al. (1992) Translocations involving band 3q27 and Ig gene regions in non-Hodgkin's lymphoma, Blood 79: 2527.
- 35 10. Ye, B.H., et al. (1993) Alterations of a zinc-finger encoding gene, BCL-6, in diffuse large-cell lymphoma, Science 262:747.
11. Knowles, D.M. (ed.) (1992) Neoplastic Hemopathology, Williams & Wilkins, Baltimore, MD.

12. Armitage, P., (1977) Statistical methods in medical research, Blackwell Scientific Publications, London, p. 11.
- 5 13. Chaganti, R.S.K., et al. (1989) Specific translocations in non-Hodgkin's lymphoma: incidence, molecular detection, and histological and clinical correlations, Cancer Cells 7:33.
- 10 14. Lo Coco, F., et al. (1993) p53 mutations are associated with histologic transformation of follicular lymphoma, Blood 82:2289.

15 EXPERIMENTAL DETAIL SECTION IV

Introduction:

20 Non-Hodgkin lymphomas (NHL) represent one of the most common malignancies associated with human immunodeficiency virus (HIV) infection, and are recognized as an acquired immunodeficiency syndrome (AIDS)-defining condition (1-3). Since their initial observation in 1982 (4), the incidence of AIDS-associated NHL (AIDS-NHL) has been consistently increasing (1, 2), and they now represent the most frequent HIV-associated malignancy in some AIDS risk groups, namely the hemophiliacs (5). Indeed, some estimates project that 10 to 20% of all new NHL cases in the United States may eventually be related to AIDS (6).

25

30

35 AIDS-NHL are almost invariably B-cell derived NHL (1, 2, 7-12). When compared with NHL of similar histology arising in the immunocompetent host, AIDS-NHL display distinctive clinical features, including late stage at presentation, poor prognosis, and the frequent

involvement of extranodal sites (1, 2, 7-12). Systemic AIDS-NHL are histologically heterogeneous, and have been initially classified into three distinct categories, including small non cleaved cell lymphoma (SNCCCL), large non cleaved cell lymphoma (LNCCL), and large cell-immunoblastic plasmacytoid lymphoma (LC-IBPL) (7, 9). Subsequently, most investigators have agreed to classify LNCCL and LC-IBPL as a single category under the term of diffuse large cell lymphoma (DLCL).

Some progress has been made in elucidating the molecular pathogenesis of AIDS-SNCCCL (1-3). AIDS-SNCCCL is associated at variable frequency with multiple genetic lesions, including Epstein Barr virus (EBV) infection, c-MYC translocation, RAS gene family mutation, and p53 inactivation by point mutation and allelic loss (1, 3, 13-25). On the other hand, the pathogenesis of AIDS-DLCL is relatively less defined. EBV infection appears to be the only genetic lesion associated with a significant fraction of these tumors, particularly with the subset displaying plasmacytoid features, p53 lesions have not been found and c-MYC activation is restricted to a small minority of cases (1-3, 13-25).

Materials and Methods:

Pathologic samples. Biopsy samples of lymph node, bone marrow, peripheral blood, or other involved organs from forty patients with AIDS were collected during the course of standard diagnostic procedures. Thirty-two samples were derived from patients referred to the Department of Pathology, New York University, New York, NY or to the Department of Pathology, Columbia University, New York, NY. Eight samples were derived from patients referred to the Departments of Hematology

and Pathology, University of Southern California School of Medicine, Los Angeles, CA. Diagnosis was based on analysis of histopathology, immunophenotypic analysis of cell surface markers, and immunogenotypic analysis of Immunoglobulin (Ig) gene rearrangement (32). In most cases, the fraction of malignant cells in the pathologic specimen was greater than 80%, as determined by cell suspension cytofluorometric or tissue section immunohistochemical analysis of cell surface markers and by Ig gene rearrangement analysis.

DNA extraction and Southern blot analysis. DNA was purified by digestion with proteinase K, "salting out" extraction, and precipitation by ethanol (33). For Southern blot analysis (34), 6 μ g of DNA was digested with the appropriate restriction endonuclease, electrophoresed in a 0.8% agarose gel, denatured, neutralized, transferred to Duralon filters (Stratagene, LA Jolla, CA), and hybridized to probes which had been 32 P-labeled by the random primer extension method (35). Filters were washed in 0.2 X SSC (NaCl/Na citrate)/0.5% sodium dodecyl sulphate (SDS) for 2 hours at 60°C and then autoradiographed using intensifying screens (Quanta III; Dupont, Boston, MA).

DNA probes. Immunoglobulin gene rearrangement analysis was performed using a J_H probe (36) (a gift of Dr. Korsmeyer) on *Hind*III, *Eco*RI, and *Bam*HI digests. The organization of the *BCL-6* locus was investigated by hybridization of *Xba*I, *Bam*HI, and *Bgl*II digested DNA to the human *BCL-6* probe Sac4.0 (26-27). In selected cases, a second probe representative of the *BCL-6* locus, Sac0.8, was also used. The organization of the *c-MYC* locus was analyzed by hybridization of *Eco*RI and *Hind*III digested DNA to the human *c-MYC* locus was analyzed by hybridization of *Eco*RI and *Hind*III digested

DNA to the human c-MYC probe MC413RC, representative of the third exon of the c-MYC gene (37). The presence of the EBV genome was investigated with a probe specific for the EBV termini (5.2 Kb BamHI-EcoRI fragment isolated from the fused BamHI terminal fragment NJ-het) (38).

Experimental Results:

Forty cases of systemic AIDS-NHL were studied, including 13 SNCLL and 24 DLCL (8 LNCLL and 16 LC-IBPL). In addition, three cases of CD30+ lymphomas, which have been sporadically reported in AIDS (39), were also included. All cases displayed a predominant monoclonal B-cell population as determined by Ig gene rearrangement analysis.

Analysis of BCL-6 rearrangements. The BCL-6 gene contains at least 9 exons spanning approximately 26 Kb of genomic DNA (27). Sequence analysis has shown that the first exon is non-coding and that the translation initiation codon is located within the third exon (27). Rearrangements of BCL-6 can be detected by Southern blot analysis using a probe (Sac4.0) and restriction enzymes (BamHI and XbaI) which, in combination, explore a region of 15.2 Kb containing the 5' portion of the BCL-6 gene (27) (Figures 14A-14C). This same region was previously shown to contain the cluster of chromosomal breakpoints detected in NHL of the immunocompetent host (27, 29). Cases showing an abnormally migrating band in only one digest were further studied by hybridizing the Sac4.0 probe to additional digests (BglIII) or, alternatively, by hybridizing BamHI and XbaI digests to a probe (Sac0.8) derived from the BCL-6 first intron, which, being located 3' of the breakpoint cluster, explores the reciprocal chromosome 3 (Figures 14A-14C). Only cases

showing abnormally migrating bands with two restriction enzymes and/or two probes were scored as rearranged.

Rearrangements of *BCL-6* were detected 5/24 AIDS-DLCL (20.8%), both in the LNCCL (2/8; 25%) and in the LC-IBPL (3/16; 18.7%) variants (Table 3 and Figures 14A-14C). All cases of AIDS-SNCCL and CD30+ lymphomas displayed a germline *BCL-6* locus. The location of the breakpoints detected in AIDS-HNL corresponds to the pattern most commonly observed in DLCL of the immunocompetent host.

Table 3.

Frequency of *BCL-6* rearrangements in AIDS-NHL

	SNCCL ^a	DLCL ^b	CD30+NHLc
	LNNCL	LC-IBPL	
20	0/13	2/8	3/16
			0/3

^a: SNCCL, small non cleaved cell lymphoma

^b: DLCL, diffuse large cell lymphoma. The DLCL included in the panel can be further distinguished into two subgroups (LNCCL, large non cleaved cell lymphoma; and LC-IBPL, large cell immunoblastic-plasmacytoid lymphoma) as previously reported (7,9).

^c: Non-Hodgkin lymphoma expressing the CD30 cell surface antigen (39).

Other genetic lesions. The other genetic lesions investigated in the panel of AIDS-NHL included infection by EBV of the tumor clone, activation of the *c-MYC* and *RAS* proto-oncogenes, and inactivation of the *p53* tumor suppressor gene. The experimental strategies used to investigate these lesions have been described in detail elsewhere (13, 45, 40). For some of the

cases, the molecular characterization of these genetic lesions have been previously reported (13, 14, 41); for the other cases, it has been assessed in the course of this study.

5

EBV infection was assessed by Southern blot hybridization using a probe representative of the EBV termini (38) which allows to analyze clonality in EBV-infected tissues (23) (Figures 16A-16C). A monoclonal infection was detected in 5/13 (38%) SNCCCL, 17/24 DLCL (71%) [3/8 (37.5%) LNCCL and 14/16 (87.5%) LC-IBPL], and 3/3 (100%) CD30+ cases.

10

Rearrangements of c-MYC were tested by hybridizing HindIII and EcoRI digested DNAs with a probe representative of c-MYC exon 3(41) (Figures 16A-16C). Rearrangements were present in 13/13 SNCCCL (100%), 5/24 (20.8%) DLCL [2/8 (25%) LNCCL and 3/16 (18.7%) LC-IBPL], and 2/3 CD30+ cases.

15

20

Mutations of p53 and RAS were analyzed by a two step strategy. Single strand conformation polymorphism (SSCP) analysis was applied to p53 exons 5 through 9 (in 29 cases) or p53 exons 5 through 8 (in 6 cases) and to N-, K-, and H-RAS exons 1 and 2 (in 29 cases); cases displaying an altered electrophoretic pattern by SSCP were further studied by DNA direct sequencing of the PCR product. p53 mutations were scored in 8/13 (61.5%) SNCCCL, but in none of the DLCL tested (0/22). Finally, RAS activation by point mutation was positive in 3/13 (23%) SNCCCL and in 1/16 (6%) DLCL tested.

25

30

The molecular features of the cases displaying BCL-6 rearrangements are listed in Table 4. Overall, BCL-6 rearrangements were detected both in the presence and in the absence of clonal EBV infection of the tumor,

35

whereas c-MYC alterations and p53 mutations were consistently absent in the cases displaying BCL-6 rearrangements.

Table 4.

Molecular features of AIDS-DLCL^a

	PATIENT	HISTOL. ^b	CLONALITY	BCL-6	EBV	c-MYC	p53	RAS
5	DK782	LNCCL	+	+	-	-	-	-
	DK1178	LNCCL	+	+	-	-	-	-
	DK1028	LNCCL	+	-	-	-	-	-
	DK3973	LNCCL	+	-	+	-	-	-
10	DK773	LNCCL	+	-	-	+	-	-
	RDF834	LNCCL	+	-	+	+	-	-
	DK1452	LNCCL	+	-	-	-	-	-
	DK64	LNCCL	+	-	+	-	-	+
	DK771	LC-IBPL	+	+	+	-	-	-
15	K827	LC-IBPL	+	+	+	-	-	-
	DS16	LC-IBPL	+	+	+	-	-	ND
	DK3537	LC-IBPL	+	-	+	+	-	-
	DK3357	LC-IBPL	+	-	+	-	-	-
	DK63	LC-IBPL	+	-	+	-	-	-
20	DK1446	LC-IBPL	+	-	+	+	-	-
	DK3479	LC-IBPL	+	-	-	-	-	-
	DK2092	LC-IBPL	+	-	+	-	-	-
	DS17	LC-IBPL	+	-	-	-	-	ND
	DS45	LC-IBPL	ND	-	+	-	-	ND
25	DS46	LC-IBPL	+	-	+	+	-	ND
	DS93	LC-IBPL	+	-	+	-	-	ND
	DS136	LC-IBPL	+	-	+	-	-	ND
	DS155	LC-IBPL	+	-	+	-	-	ND
	DS165	LC-IBPL	+	-	+	-	-	ND

30 ^a: The results of the analysis of EBV, c-MYC, p53 and RAS of some of these cases have been previously reported (14, 15, 41).

35 ^b: LNCCL, large non cleaved cell lymphoma; LC-IBPL, large cell-immunoblastic plasmacytoid lymphoma

^c: ND, not done

Experimental Discussion:

Diffuse large cell lymphoma (DLCL) represents the most
5 frequent type of AIDS-NHL in the HIV-infected adult
(8). Despite its epidemiologic relevance, the
molecular pathogenesis of these tumors is largely
unclarified (3). Analysis of the genomic
10 configuration of *BCL-6* in a panel of AIDS-NHL
indicates that *BCL-6* rearrangements are involved in
approximately 20% of AIDS-DLCL, whereas they are
consistently negative in AIDS-SNCCL. In this respect,
BCL-6 rearrangements may be considered the first
15 identified genetic lesion specific for the DLCL type
among AIDS-NHL. *BCL-6* rearrangements are present in
both subgroups of DLCL, i.e. LNCCL and LC-IBPL, and
occur both in the absence and in the presence of EBV
infection of the tumor clone (Table 4). On the other
20 hand, *BCL-6* rearrangements were never detected in
AIDS-DLCL carrying *c-MYC* alterations (Table 4).

The molecular pathway leading to AIDS-SNCCL involves
c-MYC rearrangements, *p53* mutations, and EBV infection
25 in 100%, 60%, and 40% of the cases, respectively (13-
26). The presence of somatic hypermutation in the
immunoglobulin variable regions utilized by AIDS-SNCCL
points to chronic antigen stimulation as an additional
mechanism in the development of these tumors. The
second genetic pathway is associated with AIDS-DLCL,
30 involves EBV in the large majority of cases, as well
as *c-MYC* and/or *BCL-6* rearrangements in a fraction of
cases (13-26). These distinct pathogenetic mechanisms
correlate with a number of clinical features which
distinguish AIDS-SNCCL from AIDS-DLCL, including
35 different age of onset and different CD4 counts at the
time of lymphoma development (1,2,8).

Results suggest that the frequency of BCL-6 rearrangements in AIDS-DLCL is significantly lower than that in DLCL in the immunocompetent host, where BCL-6 rearrangements occur in more than 40% of the cases. It is possible that the genetic pathogenesis of these two groups of tumors is different, and that the molecular mechanisms active in AIDS-DLCL are characterized by a higher degree of heterogeneity. Among DLCL in the immunocompetent host, BCL-6 rearrangements are associated with distinct clinical features, including the extranodal origin of the lymphoma and the lack of bone marrow involvement. In addition, the presence of this rearrangement appears to represent a favorable prognostic marker.

REFERENCES FOR SECTION IV:

1. Karp, J.E., and Broder, S. (1991) Acquired Immunodeficiency Syndrome and non-Hodgkin's lymphomas, Cancer Res. 51:4743.
2. Levine, A.M. (1992) Acquired Immunodeficiency Syndrome-related lymphoma, Blood 80:8.
3. Gaidano, G., and Dalla-Favera, R. (1992) Biologic aspects of human immunodeficiency virus-related lymphoma, Curr. Opinion Oncol. 4:900.
4. Ziegler, J.L., et al. (1982) Outbreak of Burkitt's like lymphoma in homosexual men, Lancet 2:631.
5. Ragni, M.V., et al. (1993) Acquired immunodeficiency syndrome-associated non-Hodgkin's lymphomas and other malignancies in patients with hemophilia, Blood 81:1889.

6. Gail, M.H., et al. (1991) Projection of the incidence of non-Hodgkin's lymphoma related to acquired immunodeficiency syndrome, J. Natl. Cancer Inst. 83:965.
- 5 7. Raphael, B.G., and Knowles, D.M. (1990) Acquired immunodeficiency syndrome-associated lymphomas, Sermin. Oncol. 17:361.
- 10 8. Beral, V., et al. (1991) AIDS-associated non-Hodgkin lymphoma, Lancet 337:805.
- 15 9. Knowles, D.M., et al. (1988) Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS), Ann. Int. Med. 108:744.
- 20 10. Levine, A.M., et al. (1984) Development of B-cell lymphoma in homosexual men, Ann. Intern. Med. 100:7.
- 25 11. Carbone, A., et al. (1991) A clinicopathologic study of lymphoid neoplasias associated with human immunodeficiency virus infection in Italy, Cancer 68:842.
- 30 12. Ioachim, H.L., et al. (1991) Acquired immunodeficiency syndrome-associated lymphomas: Clinical, pathologic, immunologic, and viral characteristics of 111 cases, Hum. Pathol. 22:659.
- 35 13. Ballerini, P., et al. (1993) Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma, Blood 81:166.
14. Gaidano, G., et al. (1993) In vitro establishment of AIDS-related lymphoma cell lines: phenotypic

characterization, oncogene and tumor suppressor gene lesions, and heterogeneity in Epstein-Barr virus infection, Leukemia 7:1621.

- 5 15. Groopman, J.E., et al. (1986) Pathogenesis of B-cell lymphoma in a patient with AIDS, Blood 67:612.
- 10 16. Pelicci, P.-G., et al. (1986) Multiple monoclonal B cell expansions and c-myc oncogene rearrangements in acquired immune deficiency syndrome-related lymphoproliferative disorders. Implications for lymphomagenesis, J. Exp. Med. 164:2049.
- 15 17. Subar, M., et al. (1988) Frequent c-myc oncogene activation and infrequent presence of Epstein-Barr Virus genome in AIDS-associated lymphoma, Blood 72:667.
- 20 18. Haluska, F.G., et al. (1989) Molecular resemblance of an AIDS-associated lymphoma and endemic Burkitt lymphomas: implications for their pathogenesis, Proc. Natl. Acad. Sci. USA 86:8907.
- 25 19. Meeker, T.C., et al. (1991) Evidence for molecular subtypes of HIV-associated lymphoma: division into peripheral monoclonal, polyclonal and central nervous system lymphoma, AIDS 5:669.
- 30 20. Epstein-Barr virus and AIDS associated lymphomas. Editorial, Lancet 338:979, (1991).
- 35 21. Hamilton-Dutoit, S.J., et al. (1991) Detection of Epstein-Barr virus genomes in AIDS related lymphomas: sensitivity and specificity of in situ hybridization compared with Southern blotting, J.

Clin. Pathol. 44:676.

- 5 22. Hamilton-Dutoit, S.J., et al. (1991) AIDS-related lymphoma. Histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization, Am. J. Pathol. 138:149.
- 10 23. Neri, A., et al. (1991) Epstein-Barr virus infection precedes clonal expansion in Burkitt's and acquired immunodeficiency syndrome-associated lymphoma, Blood 77:1092.
- 15 24. Nakamura, H., et al. (1993) Mutation and protein expression of p53 in acquired immunodeficiency syndrome-related lymphomas, Blood 82:920.
- 20 25. Carbone, A., et al. (1993) Human immunodeficiency virus-associated systemic lymphomas may be subdivided into two main groups according to Epstein-Barr viral latent gene expression, J. Clin. Oncol. 1:1674.
- 25 26. Ye, B.H., et al. (1993) Cloning of BCL-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma, Cancer Res. 53:2732.
- 30 27. Ye, B.H., et al. (1993) Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large cell-lymphoma, Science 262:747.
- 35 28. Baron, B.W., et al. (1993) Identification of the gene associated with the recurring chromosomal translocations t(3;14)(q27;q32) and t(3;22)(q27;q11) in B-cell lymphomas, Proc. Natl. Acad. Sci. USA 90:5262.

29. Kerckaert, J.-P., et al. (1993) LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphoma, Nature Genet. 5:66.
- 5
30. Deweindt, C., et al. (1993) Cloning of a breakpoint cluster region at band 3q27 involved in human non-Hodgkin's lymphoma, Genes, Chrom. & Cancer 8:149.
- 10
31. Bastard, C., and Tilly, H. (1993) Response to letter "t(2;3)(p12;q27) in Hodgkin's disease of a human immunodeficiency-virus positive patient with hemophilia", by Schlegelberger B, Grote W, Wacker HH, Bartels H., Blood 81:265.
- 15
32. Knowles, D.M., et al. (1986) T-cell receptor Beta chain (T_B) gene rearrangements: genetic markers of T-cell lineage and clonality, Hum. Pathol. 17:546.
- 20
33. Miller, S.A., et al. (1988) A simple salting out procedure for extracting DNA from human nucleated cells, Nucleic Acid Res. 16:1215.
- 25
34. Sambrook, J., et al. (1989) Molecular cloning: a laboratory manual. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory.
- 30
35. Feinberg, A.P., and Vogelstein, B. (1983) A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity, Anal. Biochem. 132:6.
- 35
36. Korsmeyer, S.J., et al. (1981) Developmental hierarchy of immunoglobulin gene rearrangement in human leukemic pre-B cells, Proc. Natl. Acad.

Sci. USA 78:7096.

- 5 37. Dalla-Favera, R., et al. (1981) Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells, Proc. Natl. Acad. Sci. USA 78:7096.
- 10 38. Weiss, L.M., et al. (1987) Epstein-Barr virus DNA in tissues of Hodgkin's disease, Am. J. Path. 129:86.
- 15 39. Chadburn, A., et al. (1993) CD30(Ki-1) positive anaplastic large cell lymphomas in individuals infected with the human immunodeficiency virus, Cancer 72:3078.
- 20 40. Gaidano, G., et al. (1991) p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia, Proc. Natl. Acad. Sci. USA 88:5413.
- 25 41. Shibata, D., et al. (1993) Epstein-Barr virus-associated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus, Blood 81:2102.

EXPERIMENTAL DETAIL SECTION V

Introduction:

30

The group of diffuse lymphomas with a large cell component (DLCL), including diffuse mixed, immunoblastic, and large cell subtypes, and the group of follicular lymphomas, each comprise about 40 per cent of non-Hodgkin's lymphomas (NHL) in this country (1). Together, the incidence of NHL is increasing at 3 to 4 per cent a year, a rate second only to that of

35

malignant melanoma and lung cancer in women (2). Despite significant advances in treatment, approximately half of patients with DLCL will succumb to their disease, although "high risk" individuals may successfully be treated by intensive chemotherapy and radiotherapy regimens including autologous bone marrow transplantation (3-7). The formulation of prognostic models allow clinical trials to be directed toward groups of patients with different risks for failure after conventional treatment (5).

Cytogenetic studies as well as molecular genetic analysis of alterations involving proto-oncogenes and tumor suppressor genes have provided insights into the pathogenesis of NHL, and have also contributed diagnostic and prognostic markers (8,9). Examples include rearrangements of the BCL-2 gene at 18q21 observed in up to 85 per cent of follicular lymphomas, the BCL-1 gene at 11q13 rearranged in intermediate differentiation NHL, and the MYC gene, perturbed in Burkitt's lymphoma (8,9). While no recurring genetic abnormality has been specifically associated with diffuse large cell lymphoma, rearrangement of BCL-2 has been observed in 20 to 30 per cent of cases, where it has been associated with decreased overall or disease free survival (10-12). Chromosomal translocations including those involving the MYC proto-oncogene, while noted in DLCL, were not as prognostically significant as other recurring chromosomal abnormalities (8,13).

BCL-6 (14-19) rearrangement is found to denote a subset of DLCL characterized by extranodal presentation and a favorable clinical outcome. These results indicate that, in concert with other clinical features, this molecular marker may be utilized as a prognostic indicator at the time of diagnosis.

Materials and Methods:

This study was comprised of 102 cases of DLLC studied at diagnosis with documented clonal rearrangement of the IGH gene and DNA available for further analysis, derived from 229 DLLC serially ascertained over a nine year period. Excluded were 127 cases studied at relapse, T cell DLLC, or cases for which no DNA was available. For this study, DLLC was defined as lymphomas of diffuse large cleaved, non-cleaved, immunoblastic, or mixed subtype, according to the International Working Formulation (20) as classified by a hematopathologist (DCS or DF). Cytogenetic analysis was attempted on each of the specimens as previously described (21). For detection of BCL-6 rearrangements, DNA from each case was digested with BamHI and XbaI and subjected to Southern blot analysis utilizing a 4kb SacI-SacI fragment of the BCL-6 gene as a probe (19). Cases which did not yield metaphases for karyotypic analysis were also analyzed for rearrangement of the MBR and MCR breakpoint regions of the BCL-2 gene, as previously described (11). Aggregate descriptions of 47 of the cases in the current series were included in prior reports of cytogenetic abnormalities in DLLC (11, 13, 14). A detailed molecular analysis of 8 cases (nos. 352, 755, 1098, 1254, 1403, 1444, 1445) demonstrating BCL-6 rearrangement has been reported separately (19).

For each case, clinical data were compiled as previously described (22). Stage was assessed according to the modified Ann Arbor criteria (25). For the purposes of separate evaluation of number of extranodal sites of disease, radiographs or pathologic involvement of these sites were scored. In the quantitation of extranodal sites of disease as a prognostic variable, bone marrow, but not splenic

involvement was scored, in accord with the International Prognostic Index (5).

5 Clinical endpoints including complete response and freedom from progression were defined as previously described (3). Of 102 patients with DLLC genetically analyzed prior to cytotoxic treatments, 93 received systemic chemotherapy. Nine patients with early stage disease were treated by surgical resection and/or radiation therapy. All patients were treated with curative intent. Chemotherapy treatments were classified into three groups: NHL-4, CHOP and BACOP (1st generation); m-BACOD, NHL-7 (2nd generation); MCOP_B, NHL-9, NHL-14, NHL-15, L-20 (3rd generation) (4,24,29). Eight patients expired before completion of therapy, with incomplete staging evaluations, or of infectious complications during or shortly after treatment. These cases were considered not valuable for the determination of remission status, but were included in the analysis of overall survival and freedom from progression. One patient was judged to be a complete remission which was confirmed by autopsy after expiration due to infectious complications 3 weeks after completion of protocol treatment. All deaths, regardless of cause were considered as endpoints in the analysis of overall survival. Median survival was determined by the method of Kaplan and Meler (30). Analysis of correlations between gene rearrangements and clinical features were performed utilizing Fisher's exact test (13). Means were compared utilizing two sample t-tests. Univariate comparisons of survival and duration free from progression were made by log rank test. Survival and freedom from progression estimates are quoted with confidence intervals (CI) given in parentheses. Multivariate analysis was performed utilizing the Cox regression model (31). Stepwise

multiple logistic regression was used in the multivariate analysis of factors prognostic for achieving a complete response. For all statistical analyses, a $P < 0.05$ based on a 2-sided test was considered significant.

Experimental Results:

Of 102 cases of DLCL studied at diagnosis, 23 demonstrated BCL-6 rearrangement, 21 demonstrated t(14;18) or rearrangement of BCL-2, and 58 demonstrated no evidence of either BCL-6 or BCL-2 rearrangement. Representative results of hybridization analysis for rearrangement of BCL-6 are depicted in Figures 17A-17B. The clinical characteristics of groups according to BCL-6 or BCL-2 rearrangement are summarized in Table 5. The histologic subtypes and clinical features of the BCL-6 rearranged cases are shown in Table 6.

The key to Table 6 is as follows: Underlining signifies site from which biopsy was performed. Histology: DLC = diffuse large cell; IMB = immunoblastic; DML = diffuse mixed lymphoma; LDH = lactate dehydrogenase in units/ml; (B) = bulky disease (> 8 cm or 1/3 thoracic diameter); CHOP = cyclophosphamide, daunorubicin, vincristine, prednisone; MACOPB = methotrexate, daunorubicin, cyclophosphamide, vincristine, prednisone, bleomycin; MBACOD = same drugs as MACOPB with dexamethasone instead of prednisone and drugs in different schedule; PrCyBom - drugs of MACOPB plus cytosine arabinoside, etoposide, methotrexate; L-20 = vincristine, cyclophosphamide, methotrexate, daunorubicin, prednisone, cytosine arabinoside, 1-asparaginase, BCNU, 6-mercaptopurine, dactinomycin; 1-20 includes randomization to autologous transplantation; NHL-7 =

CHOP plus methyl GAG, etoposide(36), NHL-14 = short course PrCyBom; NHL-15 = high dose daunorubicin, vincristine, cyclophosphamide(29); RT = radiation therapy; SURG = surgery CR = complete response; SCR = surgical complete response (all evaluable disease resected); PR = partial response; "+" = alive at last follow-up; e = expired; rel = relapse; NE = not evaluable; * = Patient 1445 had a history of low grade NHL of eyelid 7 years earlier, treated by radiotherapy. # Skin involvement of patient 252 was not noted in a prior report (14) and patient 1445 had a history of low grade NHL of eyelid 7 years earlier, treated by radiotherapy.

While each of the BCL-6 rearranged cases was classified as a DLCL, the range of morphologies included diffuse large cell (cleaved and non-cleaved), and less frequently, immunoblastic, or mixed histologies. Extensive necrosis and extranodal extension were common histologic features, and were present in one of two cases of BCL-6 rearrangement which did not show clinical evidence of extranodal disease.

The BCL-6 rearranged cases had a mean age of 64.1 years at presentation and a high frequency of extranodal involvement by disease; 19 of 23 cases had stages IE, IIE, IIIE or stage IV disease, compared to 48 of 79 of BCL-6 germline cases ($p=0.07$). Extranodal sites included muscle or subcutaneous tissues (6 cases), stomach (5 cases), lung or pleura (5 cases), skin, breast, bowel, thyroid, pancreas, or kidney, as assessed by biopsy or radiographic abnormalities which improved after chemotherapy. Of the 7 cases with state IE or IIE decrease, 5 were primary extranodal lymphomas, while 2 were extranodal extensions from a primary nodal site. Two cases were primary splenic

lymphomas. In two cases, there was only peripheral adenopathy. Compared to BCL-6 germline cases, there was no significant difference in the proportion of BCL-6 rearranged cases with stage IV disease. Bone marrow involvement was observed in 15 of 75 BCL-6 germline cases biopsied, compared to only 1 of the 23 stage IV BCL-6 rearranged cases ($P=0.1$).

All but one of the 23 patients with BCL-6 rearrangement at the time of diagnosis received anthracycline-containing chemotherapy. This patient remained free of disease eight years after resection of a primary splenic large cell lymphoma. At median follow-up in excess of two years, 21 of the 23 patients with BCL-6 rearrangement survived; the actuarial survival was 91 per cent (CI 80 per cent to 100 per cent). Two patients expired during or immediately following treatment; an autopsy in one case revealed no evidence of lymphoma. This patient, and 19 others were judged to have achieved a complete remission after treatment. Two patients relapsed with recurrent disease in the lung and two patients had persistent subcutaneous masses. One of the relapse patients (case 295) went on to autologous transplantation and remains free of disease 78 months post-transplant.

With respect to known prognostic variables, the proportion of the BCL-6 rearranged cohort with LDH > 500 U per liter was similar to the proportion of the BCL-6 germline DLCL (3/23 versus 13/79; $P=0.99$). Five of 23 cases of DLCL with BCL-6 rearrangement demonstrated bulky disease, compared to 35 of 79 cases without BCL-6 rearrangement ($P=0.1$). The proportion of cases with "limited stage" (I, IE, II, or IIE) disease was comparable in the cohorts with and without BCL-6 rearrangement (Table 5).

Table 5.

Characteristics of 102 cases of DLLC

		BCL-6+	BCL-6- BCL2-	BCL-6+ BCL2+
5	n=	23	58	21
	Mean age (years)	64.1	52.7	62.8
10	Mean lactate dehydrogenase (U/ml)	405	331	389
	Mean extranodal sites	1.6	.93	.81
15	Bone marrow involvement	1/23	8/54	7/21
	<u>Stage</u>			
20	I (IE)	3 (1)	3 (3)	0
	II (IIE)	7 (6)	22 (6)	5
	III (IIIE)	2 (1)	8 (2)	4
25	IV	11	25	12
	<u>Histology</u>			
	Diffuse large cell	20	53	19
30	Diffuse mixed	1	2	1
	Immunoblastic	2	3	1
	<u>Treatment</u>			
	1st generation chemo.	12	16	10
35	2nd generation chemo.	1	10	3
	3rd generation chemo.	9	24	8
	other	1	8	0
	Complete Remission	20/23	35/50	15/21
40	Rate	86%	70%	71%
	Projected survival at 36 months	91% (CI 80%-100%)	59% (CI 44%-74%)	46% (CI 21%-72%)
45				
	Projected freedom from progression at 36 months	82% (CI 66%-98%)	56% (CI 43%-70%)	31% (CI 8%-53%)
50				

Table 6.

Clinical features of 23 cases of DLLC with BCL6 rearrangement

CASE NUMBER	AGE/SEX	STAGE	EXTRANODAL SITES	HISTOLOGY	LDH (BULK)	TREATMENT	CLINICAL OUTCOME
102	66/F	IIS	spleen	DLC	3624	SURG, CHOP	CR, 96+
147	61/F	IS	spleen	DLC	365 (B)	SURG, RT	sCR, 101+
252	54/M	IV	spleen, skin [†]	DLC	126	MACOPB	CR, 88+
278	68/M	IV	pleura, iliac mass	DLC	235 (B)	MACOPB	PR, 6e
295	46/M	IV	lung	DLC	179	MACOPB, L-20	CR, rel, 97+
352	53/F	IV	stomach, liver, spleen, small bowel, pleural effusion	IMB	775 (B)	MACOPB	CR, 81+
470	74/F	IV	lung	DLC	224	CHOP	CR, 30+
534	70/F	IIES	spleen, mass involving pancreas	DLC	278 (B)	CHOP	CR, 80+
763	79/F	IIE	stomach	DLC	196	CHOP	CR, 60+
970	75/M	IV	kidney, stomach	DLC	240	NHL-14	CR, 4e
1020	60/M	IIIE	tonsil, pancreas	DLC	303	CHOP	CR, 100+
1056	63/M	IIE	stomach	DLC	213	SURG, MBACOD	CR, 100+
1058	59/M	IIE	axillary mass involving breast	DLC	206	PrCyBon	CR, 37+
1098	74/F	IV	subcutaneous masses	DML	181	RT, CHOP	PR, 36+
1189	71/M	IV	subcutaneous masses	DLC	330	CHOP	PR, 21+
1254	74/F	IIE	thyroid	DLC	196	CHOP/RT	CR, 27+
1264	76/F	IV	lung, liver, spleen, kidney	DLC	234	CHOP	CR, rel, 27+
1299	50/M	IE	deltoid mass, bone	DLC	529 (B)	PrCyBon	CR, 16+
1363	47/M	III	NONE	DLC	129	NHL-15	CR, 16+
1403	62/M	I	NONE	IMB	222	CHOP, RT	CR, 11+
1407	71/M	IIE	stomach	DLC	206	SURG, CHOP	CR, 12+
1444	70/F	IV	lung	DLC	150	CHOP	CR, 14+
1445	63/F	IV	neck mass involving muscle [†] , bone marrow	DLC	174	NHL-15	CR, 8+

Multivariate analysis of clinical outcome. The median duration free from progression of disease was not reached in the BCL-6 rearranged DLCL compared to 70 months for BCL-6 germline cases, regardless of BCL-2 status ($P=0.009$) (Figure 18A). Projected freedom from progression at 36 months was 82% (CI 66%- 98%) and 49% (CI 37%-60%), respectively. Multivariate analysis revealed that four variables, BCL-6 status, stage IV disease, bulk of disease, and LDH (log transformed) were the most powerful prognostic indicators for freedom from progression (Table 7). Multivariate analysis of survival demonstrated that bulk, LDH, BCL-6 status, and stage IV disease were the most useful predictors of overall survival ($P=0.01$, $P=0.02$, $P=0.02$, $P=0.05$, respectively).

Table 7

Multivariate analysis of freedom from progression			
Variables selected into Cox regression model	Relative Risk	P value (Wald chi square)	
BCL-6 rearranged	0.18 (CI .04-.78)	0.007	
Bulky disease	2.4 (CI 1.3-7.4)	0.01	
Stage IV disease	2.1 (CI 0.98-5.2)	0.03	
LDH (log transformed)	1.6 (CI 1.1-3.9)	0.05	

The prognostic value of BCL-6 gene status was compared to risk variables calculated according to the International Prognostic Index³, including serum LDH level, stage, performance status, and number of extranodal sites. A cox regression analysis confirmed

the independent prognostic value of BCL-6 gene status; patients with BCL-6 rearrangement had a relative risk (RR) of dying of .09 (CI .02 to .42) compared to patients without BCL-6 rearrangement, controlling for the other prognostic variables in the model ($P=0.002$).

When cases were considered with respect to BCL-2 status, the BCL-2 rearranged cases demonstrated a trend for a decreased survival compared to BCL-2 germline cases, regardless of BCL-6 status ($P=0.12$). When BCL-6 and BCL-2 status were considered together (Figure 18B), BCL-6 rearranged cases demonstrated a projected actuarial survival at 36 months of 91% (CI 80%-100%) compared to 59% (CI 44%-74%) for the BCL-6 germline/BCL-2 germline cohort, and 46% (CI 21%-72%) for the BCL-2 rearranged cohort. While the logrank test between these three cohorts demonstrated a difference in survival ($P=0.02$, Figure 18B), the major factor driving the significant summary P value was the better survival of the BCL-6 rearranged cohort. The projected freedom from progression at 36 months was 82% (CI 66%-98%), 56% (CI 43%-70%) and 31% (CI 8%-53%) for the three groups. Median follow-up for survivors was two years. BCL-2 rearrangement did not emerge as an independent prognostic marker in the multivariate analysis of survival or freedom from progression.

There was also no prognostically significant effect of generation of chemotherapy treatment on survival, or freedom from progression ($P=0.95$, 0.21 , respectively). There was a trend for a higher complete response rate among the BCL-6 rearranged cohort (Table 5, $P=0.1$), although logistic regression revealed that only the clinical parameters LDH, stage IV, and bulk of disease were independent predictors of response.

Relationship between BCL-6, BCL-2, and 8q24

rearrangements. Of the 79 cases which lacked BCL-6 rearrangement, 21 demonstrated t(14;18)(q32;q21) or rearrangement of BCL-2 by molecular analysis. These cases were characterized by an older age at diagnosis, but were similar to the larger cohort of BCL-2 negative, BCL-6 negative cases with respect to LDH, and distribution of histologies (Table 6).

Nine cases of DLCL demonstrated t(8;14)(q24;q32). Three of these biopsies were from extranodal sites including liver, bone and soft tissue. Two additional cases were splenic lymphomas. In two cases, t(8;14) bearing DLCL also demonstrated BCL-6 rearrangement. There was no impact on survival of the t(8;14) in DLCL with or without BCL-6 rearrangement. The two cases of t(8;14) with co-incident BCL-6 rearrangement did not show evidence of histologic transformation or other unusual histologic features. One of these cases (no. 147) was the single case treated by splenectomy and radiation therapy alone. The second case was the single BCL-6 rearranged case successfully salvaged by autologous transplantation.

Cytogenetic features, including the relationship between 3q27 and BCL-6 rearrangement. Of the 65 DLCL with karyotypic abnormalities, 14 demonstrated translocations and one a deletion affecting band 3q27; only 11 among these 15 cases showed rearrangement of BCL-6. Five cases with apparently normal chromosomes demonstrated BCL-6 rearrangements by DNA analysis.

Experimental Discussion:

As a group, DLLC are among the most common forms of NHL seen in this country (1). These tumors have not, however, been associated with a characteristic genetic abnormality (8). Seen in the vast majority of follicular lymphomas, t(14;18)(q32;q21) or its molecular equivalent, BCL-2 rearrangement, have been observed in 20 to 30 per cent of DLLC (8). In such cases, the t(14;18) may reflect a follicular origin of these tumors. The recognition of translocations involving 3q27 and the sites of IG genes, 14q32, 22q11, and 2p12, in predominantly diffuse NHL led to the molecular cloning of BCL-6 (14-19). While not unique to diffuse large cell lymphomas, translocations affecting 3q27 were observed only in 7 of > 200 cases off follicular NHL with abnormal karyotype reported in catalog of chromosome abnormalities in cancer (32). Of 28 cases of follicular NHL analyzed in a prior study, none demonstrated rearrangement of BCL-6 (19). BCL-6 rearrangement was established as the most common genetic lesion specific to DLLC at the time of diagnosis.

Unlike 18q21 translocations in NHL which, to date only have involved IG gene loci as reciprocal partners, 3q27 translocations demonstrated a marked promiscuity of rearrangement partners. In addition to the sites of the IG genes, reciprocal translocations involving the 3q27-29 region with at least 12 other loci; a total of 79 DLLC with 3q27 translocations has been demonstrated.

Since 4 tumors in the current series with documented 3q27 aberrations did not reveal BCL-6 rearrangement with the probe used in this study, the true frequency of BCL-6 rearrangement in DLLC at diagnosis may be

higher than the 23 per cent rate reported here. Additional breakpoints may be documented outside the recognized break cluster region of BCL-6 (19), in neighboring genes such as EV-1 (34), or in other genes not yet described. Such molecular heterogeneity is not unique in NHL; seemingly identical chromosomal translocations have been shown to demonstrate a diversity of breakpoints possibly involving different genes (35).

The frequent occurrence of BCL-6 rearrangement in DLCL characterized by extranodal involvement represents one of the few genetic markers for this subset of lymphoma (8). Rearrangements of BCL-1, BCL-2, or BCL-3 have been documented infrequently in extranodal lymphomas (36-38), while 5 of 12 gastric lymphomas in one series demonstrated MYC (8q24) rearrangement (38). The current series did not confirm the association between 8q24 rearrangement and gastric lymphoma, although t(8;14) was seen in five cases of extranodal lymphoma, one of which also showed BCL-6 rearrangement. The proportion of BCL-6 rearranged cases with stages IE, IIE, IIIE, or IV disease was higher than the proportion of BCL-6 germline DLCL; in the latter group, stage IV disease was more commonly due to bone marrow involvement. Whether this association with extranodal involvement of disease reflects an effect of the primary deregulation of BCL-6 or "secondary" genetic events associated with tumor progression (8,21) is unclear. The observation of t(3;22), t(2;3), or t(3;14) as solitary cytogenetic abnormalities in some tumors (14,15), is consistent with a primary pathogenetic role for this translocation.

While this analysis and two other reports did not confirm the very short survival of BCL-2 rearranged

DLLC initially reported (10, 12, 13, 39), the BCL-2 rearranged DLLC did demonstrate a trend for a poorer overall survival. The finding of a favorable prognosis for the subset of stage IE-IIIE extranodal
5 DLLC with BCL-6 rearrangement is consistent with prior reports of a good prognosis associated with localized extranodal large cell NHL treated with surgery or radiotherapy (40). Extranodal involvement in advanced
10 stage disease, noted in the majority of the BCL-6 rearranged cases, has generally been considered a poor prognostic factor in large series of DLLC, although the negative impact of this feature was most evident when combined with other adverse indicators such as bulk, high LDH, or low performance status (5, 22, 41).
15 In contrast, bone marrow involvement, observed in 22 percent of DLLC, and considered an extranodal site in the International Prognostic Index (5), was rare in the BCL-6 rearranged cohort. The favorable treatment outcome of the BCL-6 cohort, must also be tempered by
20 the observation of relapse or residual disease in 3 of the patients still alive. An additional relapse case remains in remission 6 years after "salvage" autologous transplantation.

25 The BCL-6 rearranged cohort of DLLC also possessed other clinical markers of favorable prognosis; although comparable with respect to LDH and proportion with stage I-IIIE disease, the proportion of cases
30 with bulky disease or bone marrow involvement was lower in the BCL-6 rearranged cohort. Multivariate analysis suggested, however, that BCL-6 gene rearrangement added independent prognostic power when analyzed together with clinically-derived variables of the International Prognostic Index (5). This
35 observation is illustrated by case 352, which displayed both BCL-6 rearrangement as well as clinical features consistent with a high level of risk in the

International Index (elevated LDH, extensive extranodal involvement, low performance status, and stag IV disease), but who attained a durable remission.

5

Because of issues of toxicity versus efficacy of autologous bone marrow transplantation or peripheral stem cell rescue, the identification of both favorable and unfavorable prognostic markers offers the potential to stratify treatment approaches to DLCLC based on risk groups (4-7, 22, 41). The probability of treatment failure remains as high as 25-40 per cent for the most favorable subsets of DLCLC based on current prognostic models, highlighting the need for genetic or other prognostic markers (5). In addition to its potential diagnostic and prognostic applications, the further identification of BCL-6 breakpoint regions offers the opportunity to develop new polymerase chain reaction-derived measures of minimal residual disease (43). The availability of BCL-6 rearrangement as a new molecular marker of large cell lymphoma constitutes a potentially important clinical tool in the management of patients with this disease.

25

REFERENCES FOR SECTION V:

1. Simon, R., et al. (1988) The non-Hodgkin's lymphoma pathologic classification project; Longterm follow-up of 1153 patients with non-Hodgkin's lymphoma, Ann. Internal. Med. 109:939-945.
2. Devesa, S.S., and Fears, T. (1992) Non-Hodkin's lymphoma time trends: United States and international data, Cancer Res. 52:5432-40.

35

3. Fisher, R.I., et al. (1993) Comparison of a standard regimen (CHOP) with the intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma, N. Engl. J. Med. 328:1002-6.
- 5 4. Armitage, J.O. (1993) Treatment of non-Hodgkin's lymphoma, N. Engl. J. Med. 328:1023-30.
- 10 5. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's lymphoma prognostic factors project, N. Engl. J. Med. 329:987-94.
- 15 6. Gulati, S.C., et al. (1988) Autologous bone marrow transplantation for patients with poor-prognosis lymphoma, J. Clin. Oncol. 6:1303-13.
- 20 7. McMaster, M.L., et al. (1991) Results of treatment with high intensity, brief duration chemotherapy in poor prognosis non-Hodgkin's lymphoma, Cancer 68:233-41.
- 25 8. Offit, K., and Chaganti, R.S.K. (1991) Chromosomal aberrations in non-Hodgkin's lymphoma: biological and clinical correlations, Hematol. Oncol. Clin. North Am. 5:853-869.
- 30 9. McKeithan, T.W. (1990) Molecular biology of non-Hodgkin's lymphomas, Semin. Oncol. 1:30-42.
9. Yunis, J.J., (1989) bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma, N. Engl. J. Med. 320:1047-54.
- 35 10. Offit, K., et al. (1989) 18q21 rearrangement in diffuse large cell lymphoma: incidence and clinical significance, Br. J. Haematol. 72:178-

83.

- 5 11. Jacobson, J.O., et al. (1993) bcl-2 rearrangements in de novo diffuse large cell lymphoma, Cancer 72:231-6.
- 10 12. Offit, K., et al. (1991) Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodkin's lymphoma: clinical correlations, Blood 77:1508-15.
- 15 13. Offit, K., et al. (1989) t(3;22)(q27;q11): A novel translocation associated with diffuse non-Hodgkin's lymphoma, Blood 74:1876-79.
14. Bastard, C., et al. (1992) Translocations involving band 3q27 and Ig gene regions in non-Hodgkin's lymphoma, Blood 79:2527-31.
- 20 15. Ye, B.H., et al. (1993) Cloning of bcl6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma, Cancer Res. 53:2732-35.
- 25 16. Baron, B.W., et al. (1993) Identification of the gene associated with the recurring chromosomal translocations t(3;14)(q27;q32) and t(3;22)(q27;q11) in B-cell lymphomas, Proc. Natl. Acad. Sci. 90:5262-66.
- 30 17. Kerckaert, J.-P., et al. (1993) LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas, Nat. Genet. 5:66-70.
- 35 18. Ye, B.H., et al. (1993) Alterations of a novel zinc-finger encoding gene, bcl-6, in diffuse

large-cell lymphoma, Science 262:747-750.

- 5 19. The non-Hodkin's lymphoma pathologic classification project. National Cancer Institute sponsored study of classification of non-Hodkin's lymphomas: summary and description of a working formulation for clinical usage, Cancer 49:2112-35.
- 10 20. Offit, K., et al. (1991) Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodkin's lymphoma: correlations between recurrent aberrations, histology, and exposure to cytotoxic treatment, Genes Chromosom. Cancer 3:189-201.
- 15 21. Danieau, L., et al. (1986) Predictive model for prognosis in advanced diffuse histiocytic lymphoma, Cancer Res. 46:5372-79.
- 20 22. Carbone, P.P., et al. (1971) Report of the committee on Hodgkin's disease staging classification, Cancer Res. 31:1860-61.
- 25 23. Kempin, S., et al. (1983) Combined modality therapy of advanced nodular lymphomas, Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2:56.
- 30 24. Carrato, A., et al. (1987) Randomized comparison of CHOP versus Bleo CHOP for the treatment of diffuse NHL, Proc. Annu. Meet. Am. Soc. Clin. Oncol. 6:779.
- 35 25. Lowenthal, D.A., et al. (1987) The NHL-7 protocol: Alternating non-cross resistant chemotherapy containing methyl-GAG for diffuse non-Hodkin's lymphoma, Proc. Annu. Meet. Am. Soc.

Clin. Oncol. 6:778.

- 5 26. Warrell, R.P., et al. (1989) Short term intensive treatment of intermediate-grade non-Hodkin's lymphoma using infusional chemotherapy, Proc. Annu. Meet. Am. Soc. Clin. Oncol. 8:1054.
- 10 27. Straus, D.H., et al. (1991) Small non-Cleaved cell lymphoma (undifferentiated lymphoma/Burkitt's type) in American adults. Results with treatment designed for acute lymphoblastic leukemia in adults, Am. J. Med. 90:328-337.
- 15 28. O'Brien, J., et al. (1992) NHL-15 protocol for diffuse aggressive lymphomas: a dose intense regimen of doxorubicin, vincristine, and cyclophosphamide, Blood 80:157a.
- 20 29. Kaplan, E.L., and Meier, P. (1958) Nonparametric estimation from incomplete observations, J. Am. Stat. Soc. 53:457-81.
- 25 30. Cox, D.R. Regression models and life tables, J. R. Stat. Soc. B. 34:187-220.
31. Mitelman, F. (1991) Catalog of chromosome aberrations in cancer, New York.
- 30 32. Leroux, D., et al. (1990) Translocation t(3;22)(q27;q11) in three patients with diffuse large B cell lymphoma, Leukemia 4:373-376.
- 35 33. Fichelson, S., et al. (1992) Evi-1 expression in leukemic patients with rearrangements of the 3q25-q28 chromosomal region, Leukemia 6:93-99.

34. Ladanyi M, et al. (1992) Follicular lymphoma with t(8;14)(q24;q32). A distinct clinical and molecular subset of t(8;14)-bearing lymphomas, Blood 79:2124-30.
- 5 35. Raghoebier, S., et al. (1991) Essential differences in oncogene involvement between primary nodal and extranodal large cell lymphoma, Blood 78:2680-86.
- 10 36. Clark, H.M., et al. (1992) Cytogenetic and molecular studies of t(8;14) and t(14;19) in nodal and extranodal b:cell lymphoma, J. Pathol. 166:129-37.
- 15 37. Van Krieken, J.H.J.M., et al. (1991) Molecular genetics of gastrointestinal non-Hodkin's lymphomas: unusual prevalence and pattern of c-myc rearrangements in aggressive lymphomas, Blood 76:797-800.
- 20 38. Romaguera, J.E., et al. (1993) The clinical relevance of t(14;18)/bcl-2 rearrangement and del 6q in diffuse large cell lymphoma and immunoblastic lymphoma, Ann. Oncol. 4:51-4.
- 25 39. Rudders, R.A., et al. (1978) Primary extranodal lymphoma: Response to treatment and factors influencing prognosis. Cancer 42:406-16.
- 30 40. Coiffier, B., et al. (1991) Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy, J. Clin. Oncol. 9:211-19.
- 35 41. Schneider, A.M., et al. (1990) Treatment results

with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate and some high grade non-Hodkin's lymphomas, J. Clin. Oncol. 8:94-102.

- 5 42. Gribben, J.G., et al. (1993) Detection by polymerase chain reaction of residual cells with the BCl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for b-cell lymphoma, Blood
- 10 81:3449-87.